var title_f17_9_17552="Petroleum gauze dressing";
var content_f17_9_17552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Circumcised penis wrapped in petroleum gauze dressing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17552=[""].join("\n");
var outline_f17_9_17552=null;
var title_f17_9_17553="Engorged tick comparison";
var content_f17_9_17553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tick comparison",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Top row) Ixodes scapularis (dammini), the deer tick which transmits Lyme disease. Left to right: nymph (immature), adult male, adult female, engorged adult female. Nymphs are most common May through July. Adults appear in the fall and early spring. (Bottom row) Dermacentor variabilis, the American dog tick, which is not thought to transmit Lyme disease. Left to right: adult male, adult female, engorged adult female. Adults are most common in May, June , and July. Note that the adult dog ticks are somewhat larger than adult deer ticks, and have characteristic white markings on the dorsal (top) side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lyme Disease Research Laboratory, Maine Medical Center Research Institute, 13 Charles Street, Portland, ME 04102.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17553=[""].join("\n");
var outline_f17_9_17553=null;
var title_f17_9_17554="Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)";
var content_f17_9_17554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/39/37489\">",
"         Patient information: Bedwetting in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/9/15506\">",
"         Patient information: Nocturnal (nighttime) leg cramps (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/28/36289\">",
"         Patient information: Sleepwalking in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/9/7315\">",
"         Patient information: Bedwetting in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1820220431\">",
"      <span class=\"h1\">",
"       What are night terrors?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Night terrors (also called &ldquo;sleep terrors&rdquo;) are episodes in which children wake up suddenly at night and act very upset. They might scream and jump out of bed, as if running away from something scary. They might be sweating, breathing fast, or have a racing heart. During a night terror, you won&rsquo;t be able to calm your child down, even if you try.",
"     </p>",
"     <p>",
"      A night terror usually lasts about 10 to 20 minutes. A child might have 2 or 3 night terrors a week.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1820220446\">",
"      <span class=\"h1\">",
"       What are confusional arousals?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Confusional arousals are episodes in which children behave in a confused way because they are in between sleeping and waking up. They sit up in bed, moan, or cry. During a confusional arousal, you won&rsquo;t be able to calm your child down, even if you try. These episodes usually last 10 to 30 minutes.",
"     </p>",
"     <p>",
"      Both night terrors and confusional arousals happen in the first part of the night. They are also more likely to happen in children who have a fever or are not getting enough sleep.",
"     </p>",
"     <p>",
"      Although it can be scary to see your child having a night terror or confusional arousal, it&rsquo;s important to know that these conditions aren&rsquo;t dangerous. Also, your child won&rsquo;t remember them the next day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1820220461\">",
"      <span class=\"h1\">",
"       What are nightmares?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nightmares are very scary, sad, or upsetting dreams that wake a person up. After a nightmare, children often have trouble going back to bed.",
"     </p>",
"     <p>",
"      Nightmares usually happen in the second half of the night.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1820220476\">",
"      <span class=\"h1\">",
"       Are there other conditions that can happen during sleep?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Another common condition is sleepwalking, which is when a child walks or talks while asleep.",
"     </p>",
"     <p>",
"      Night terrors, confusional arousals, and sleepwalking sometimes run in families. Children can have 1 or more of these conditions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1820220491\">",
"      <span class=\"h1\">",
"       If my child has any of these conditions, will he or she need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. If these conditions don&rsquo;t happen very often and don&rsquo;t lead to other problems, your child will not need further tests.",
"     </p>",
"     <p>",
"      Some children might need tests to make sure another medical problem isn&rsquo;t causing their night-time behavior. Doctors might order tests if children have frequent night terrors or confusional arousals, or any of the following symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Loud snoring or gasping for breath during sleep",
"       </li>",
"       <li>",
"        Wetting the bed (if the child used to stay dry at night)",
"       </li>",
"       <li>",
"        Seizures, which are waves of abnormal activity in the brain that can make people pass out or move or behave strangely",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1820220506\">",
"      <span class=\"h1\">",
"       How can I help my child when these conditions happen?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child has a night terror or confusional arousal, you should stay with him or her until the episode stops. You should not try to wake him or her up. Once the episode stops, your child will go back to sleep.",
"     </p>",
"     <p>",
"      If your child has a nightmare, there are things you can try that might help. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Remind your child that it was only a dream and not real",
"       </li>",
"       <li>",
"        Help your child think of a new, happy ending to the dream",
"       </li>",
"       <li>",
"        Draw a picture or write about the dream, which often makes it less scary",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1820220521\">",
"      <span class=\"h1\">",
"       How can I help my child when these conditions happen?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. If these things are happening 1 or 2 times a month only, your child won&rsquo;t need any other treatment. Most children outgrow their night terrors and confusional arousals over time, but it can take 1 to 2 years.",
"     </p>",
"     <p>",
"      If these conditions are happening much more often or leading to problems, talk with the doctor or nurse. Possible treatments for night terrors and confusional arousals can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines",
"       </li>",
"       <li>",
"        A behavior plan called &ldquo;scheduled awakening&rdquo; &ndash; This involves waking your child every night (for a few moments) at a certain time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your child has frequent nightmares, the doctor or nurse might recommend that your child talk with a therapist.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1820220536\">",
"      <span class=\"h1\">",
"       Can these conditions be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Children are more likely to have night terrors and confusional arousals in certain situations, such as when they do not get enough sleep or have a fever.",
"     </p>",
"     <p>",
"      You might be able to prevent night terrors and confusional arousals by making sure your child gets enough sleep. To do this, try to stick to a regular sleep schedule. Children younger than 6 years old should get 10 to 12 hours of sleep each night. Older children should get 8 to 10 hours of sleep each night.",
"     </p>",
"     <p>",
"      If your child has trouble falling asleep or getting a good night&rsquo;s sleep, here are some things you can try:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a set bedtime and bedtime routine for your child.",
"       </li>",
"       <li>",
"        Keep your child&rsquo;s bedtime and wake-up time about the same every day (on school and non-school days).",
"       </li>",
"       <li>",
"        Make the hour before bed a quiet time, and avoid high-energy activities.",
"       </li>",
"       <li>",
"        Keep your child&rsquo;s room quiet and dark. If your child is scared of the dark, use a night light that is not too bright.",
"       </li>",
"       <li>",
"        Don&rsquo;t have a TV in your child&rsquo;s bedroom.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1820220551\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/28/36289?source=see_link\">",
"       Patient information: Sleepwalking in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/39/37489?source=see_link\">",
"       Patient information: Bedwetting in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/9/15506?source=see_link\">",
"       Patient information: Nocturnal (nighttime) leg cramps (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/9/7315?source=see_link\">",
"       Patient information: Bedwetting in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/9/17554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86004 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17554=[""].join("\n");
var outline_f17_9_17554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220431\">",
"      What are night terrors?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220446\">",
"      What are confusional arousals?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220461\">",
"      What are nightmares?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220476\">",
"      Are there other conditions that can happen during sleep?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220491\">",
"      If my child has any of these conditions, will he or she need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220506\">",
"      How can I help my child when these conditions happen?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220521\">",
"      How can I help my child when these conditions happen?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220536\">",
"      Can these conditions be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1820220551\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/9/7315?source=related_link\">",
"      Patient information: Bedwetting in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/39/37489?source=related_link\">",
"      Patient information: Bedwetting in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/9/15506?source=related_link\">",
"      Patient information: Nocturnal (nighttime) leg cramps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/28/36289?source=related_link\">",
"      Patient information: Sleepwalking in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_9_17555="Duodenojejunostomy";
var content_f17_9_17555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Duodenojejunostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 664px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duodenojejunostomy is accomplished without (A) or with (B) division of the 4th portion of the duodenum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17555=[""].join("\n");
var outline_f17_9_17555=null;
var title_f17_9_17556="Obstetrical issues in grand multiparity";
var content_f17_9_17556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Obstetrical issues in grand multiparity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17556/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17556/contributors\">",
"     Sara Ellis Simonsen, CNM, MSPH, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17556/contributors\">",
"     Michael W Varner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17556/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17556/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17556/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17556/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/9/17556/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A commonly used clinical definition of parity is the number of births (both live born infants and stillbirths) of at least 20 weeks of gestation that a woman has experienced. Nulliparas have experienced no such births, primiparas have experienced one such birth, and multiparas have experienced more than one such birth. (Pregnancy losses under 20 weeks of gestation are considered abortions, which may be spontaneous or induced. A woman's gravidity is the sum of her parity and number of abortions).",
"   </p>",
"   <p>",
"    A 1934 study suggested that multiparity increased the risk of pregnancy complications, and first introduced the term \"grand multipara.\" The author concluded that grand multiparity was dangerous because, in his study, maternal mortality increased steadily from the 5th to the 10th pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/1\">",
"     1",
"    </a>",
"    ]. On the basis of this finding, and results from subsequent studies, the clinically accepted definition of grand multiparity became parity equal to or greater than five. In the United States in 2010, nearly 190,000 women gave birth to a child that was at least their fifth birth [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VARIABLES AFFECTING THE RELATIONSHIP BETWEEN PARITY AND PREGNANCY OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between obstetric complications and parity has been studied extensively, with inconsistent findings. In additional to the usual limitations of observational data, there are several reasons for the discordancy:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Variability in the definition of parity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are discrepancies in the way clinicians define parity. A study that evaluated the definition of the term parity among obstetricians and midwives in London noted that 13 percent defined parity by the number of pregnancies irrespective of outcome, 62 percent defined parity as pregnancies of &ge;24 weeks of gestation irrespective of outcome, and 25 percent defined parity as pregnancies of &ge;24 weeks ending in live birth [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/3\">",
"     3",
"    </a>",
"    ]. Only 21 percent of those surveyed described twin pregnancies as a single parous experience.",
"   </p>",
"   <p>",
"    In addition, there is a discrepancy between the clinical definition of parity and the definition used by the United States National Center for Health Statistics (NCHS), an organization within the Centers for Disease Control. The NCHS defines parity as the number of prior live births, excluding stillbirths and fetal deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/4\">",
"     4",
"    </a>",
"    ], while most clinical investigators in the US have defined parity as the number of births (live births and stillbirths) &gt;20 weeks of gestation. Other gestational age cut-offs to define a parous event (eg, birth after 28 weeks of gestation) are used in other parts of the world.",
"   </p>",
"   <p>",
"    Finally, investigators have variably defined grand multiparity as a parity of four, five, six, seven, or eight. Thus, one study may report outcomes for women para &ge;6 compared to those &lt;6 while another reports outcomes for women para &le;5 compared to those &lt;5 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Variability in the definition of controls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have compared grand multiparas to different referent groups, including women of parity 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], 1 to 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/8\">",
"     8",
"    </a>",
"    ], 2 to 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], 2 to 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/11-14\">",
"     11-14",
"    </a>",
"    ], 1 to 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/15\">",
"     15",
"    </a>",
"    ], 1 to 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/16\">",
"     16",
"    </a>",
"    ], 2 to 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/17\">",
"     17",
"    </a>",
"    ], and the general obstetrical population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/18\">",
"     18",
"    </a>",
"    ]. This also makes it difficult to compare findings among studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonlinear relationship between parity and pregnancy outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between parity and birth outcome is not linear. This was illustrated in a cross-sectional analysis of births occurring in Australia between 1992 and 1997; women of parity 0 to 8 were studied [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/6\">",
"     6",
"    </a>",
"    ]. Multivariate analysis found that the risk of pregnancy complications was higher in nulliparas, decreased in multiparas who had had one to three deliveries, and then increased again after the fourth delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inadequate adjustment for maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the complications that have been associated with grand multiparity have also been independently associated with advanced maternal age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, maternal age is an important confounder that must be accounted for to minimize bias in interpretation of results. The importance of maternal age was illustrated in a retrospective cohort study that examined the birth outcomes of 4937 young (under 35 years of age) grand multiparas (parity &ge;5) and 83,131 young primiparas in Utah [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/7\">",
"     7",
"    </a>",
"    ]. Young grand multiparas had a significantly decreased risk for \"any intrapartum complication\" (eg, placental abruption, placenta previa, intrapartum vaginal bleeding, umbilical cord prolapse, fetal distress, malpresentation, surgical delivery, instrumented delivery) compared to young primiparas. In addition, young grand multiparas were at significantly decreased risk for any intrapartum complication when compared to older grand multiparas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Healthy person effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have had obstetrical complications in their first few pregnancies may be more likely to end their childbearing before becoming grand multiparas when compared to women who had uncomplicated pregnancies and deliveries. Thus, grand multiparas may represent a healthier group than women of lower parity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREGNANCY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multivariate analysis of parity and pregnancy outcome reported a significantly increased risk of \"any obstetric complication\" among women of parity 4, 5, 6, and 7 to 8 when compared with primiparas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/6\">",
"     6",
"    </a>",
"    ]. The obstetric complications included antepartum hemorrhage, gestational diabetes, pregnancy induced hypertension, premature rupture of the membranes, threatened premature labor, postpartum hemorrhage, and third-degree tear [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the relationship between parity and the individual components of this composite outcome has not been proven. Specifically, there are inadequate data to prove an association between grand multiparity and: gestational",
"    <span class=\"nowrap\">",
"     hypertension/preeclampsia",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/11,13,16,18,20-22\">",
"     11,13,16,18,20-22",
"    </a>",
"    ];",
"    <span class=\"nowrap\">",
"     pregestational/gestational",
"    </span>",
"    diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/11,16,17,21-23\">",
"     11,16,17,21-23",
"    </a>",
"    ];",
"    <span class=\"nowrap\">",
"     malpresentation/operative",
"    </span>",
"    delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/9,10,12,13,17,18,22,24,25\">",
"     9,10,12,13,17,18,22,24,25",
"    </a>",
"    ]; dysfunctional",
"    <span class=\"nowrap\">",
"     labor/prolonged",
"    </span>",
"    labor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/8-13,26\">",
"     8-13,26",
"    </a>",
"    ] preterm",
"    <span class=\"nowrap\">",
"     birth/low",
"    </span>",
"    birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]; neonatal intensive care unit admission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]; perinatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/6,8,10-12,18,21,22,25,28,29\">",
"     6,8,10-12,18,21,22,25,28,29",
"    </a>",
"    ]. Most reports have not distinguished between chronic hypertension, gestational hypertension, and preeclampsia or between pregestational and gestational diabetes. Furthermore, many studies have not adjusted for confounders. Reports on the risk of perinatal death have not controlled for concurrent maternal medical problems.",
"   </p>",
"   <p>",
"    On the other hand, most series have suggested that grand multiparity is associated with an increased risk of placental abnormalities, such as placenta previa and abruption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/9,12-14,25,30\">",
"     9,12-14,25,30",
"    </a>",
"    ]; postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/6,12,15\">",
"     6,12,15",
"    </a>",
"    ]; and macrosomia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17556/abstract/8,10,12,13,16,17,28\">",
"     8,10,12,13,16,17,28",
"    </a>",
"    ], although these data are also inconsistent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although grand multiparity has been associated with a number of obstetric complications, most grand multiparas have similar birth outcomes when compared with women of lower parity, especially in settings where modern obstetrical care is readily available. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pregnancy complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the complications that have been associated with grand multiparity may actually be confounded by advanced maternal age and its associated comorbidities. Thus, in patients without underlying comorbidity, grand multiparity does not appear to be an independent risk factor for severe obstetric complications, except for placenta previa and abruption. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pregnancy complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/1\">",
"      Solomons, B. The dangerous multipara. Lancet 1934; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/2\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/3\">",
"      Opara EI, Zaidi J. The interpretation and clinical application of the word 'parity': a survey. BJOG 2007; 114:1295.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. National Center for Health Statistics: NCHS Definitions. National Survey of Family Growth. June 18, 2004; December 4, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/5\">",
"      Aliyu MH, Jolly PE, Ehiri JE, Salihu HM. High parity and adverse birth outcomes: exploring the maze. Birth 2005; 32:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/6\">",
"      Bai J, Wong FW, Bauman A, Mohsin M. Parity and pregnancy outcomes. Am J Obstet Gynecol 2002; 186:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/7\">",
"      Simonsen SM, Lyon JL, Alder SC, Varner MW. Effect of grand multiparity on intrapartum and newborn complications in young women. Obstet Gynecol 2005; 106:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/8\">",
"      Lyren&auml;s S. Labor in the grand multipara. Gynecol Obstet Invest 2002; 53:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/9\">",
"      Tanbo TG, Bungum L. The grand multipara--maternal and neonatal complications. Acta Obstet Gynecol Scand 1987; 66:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/10\">",
"      Bugg GJ, Atwal GS, Maresh M. Grandmultiparae in a modern setting. BJOG 2002; 109:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/11\">",
"      Roman H, Robillard PY, Verspyck E, et al. Obstetric and neonatal outcomes in grand multiparity. Obstet Gynecol 2004; 103:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/12\">",
"      Toohey JS, Keegan KA Jr, Morgan MA, et al. The \"dangerous multipara\": fact or fiction? Am J Obstet Gynecol 1995; 172:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/13\">",
"      Babinszki A, Kerenyi T, Torok O, et al. Perinatal outcome in grand and great-grand multiparity: effects of parity on obstetric risk factors. Am J Obstet Gynecol 1999; 181:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/14\">",
"      Brunner J, Melander E, Krook-Brandt M, Thomassen PA. Grand multiparity as an obstetric risk factor; a prospective case-control study. Eur J Obstet Gynecol Reprod Biol 1992; 47:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/15\">",
"      Humphrey MD. Is grand multiparity an independent predictor of pregnancy risk? A retrospective observational study. Med J Aust 2003; 179:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/16\">",
"      Samueloff A, Mor-Yosef S, Seidman DS, et al. Grand multiparity--a nationwide survey. Isr J Med Sci 1989; 25:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/17\">",
"      Seidman DS, Armon Y, Roll D, et al. Grand multiparity: an obstetric or neonatal risk factor? Am J Obstet Gynecol 1988; 158:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/18\">",
"      Fuchs K, Peretz BA, Marcovici R, et al. The \"grand multipara\"--is it a problem? A review of 5785 cases. Int J Gynaecol Obstet 1985; 23:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/19\">",
"      Chan BC, Lao TT. Effect of parity and advanced maternal age on obstetric outcome. Int J Gynaecol Obstet 2008; 102:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/20\">",
"      Bobrowski RA, Bottoms SF. Underappreciated risks of the elderly multipara. Am J Obstet Gynecol 1995; 172:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/21\">",
"      Nassar AH, Fayyumy R, Saab W, et al. Grandmultiparas in modern obstetrics. Am J Perinatol 2006; 23:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/22\">",
"      Al JF. Grandmultiparity: a potential risk factor for adverse pregnancy outcomes. J Reprod Med 2012; 57:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/23\">",
"      Simmons D, Shaw J, McKenzie A, et al. Is grand multiparity associated with an increased risk of dysglycaemia? Diabetologia 2006; 49:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/24\">",
"      El-Toukhy T, Ramadan G, Maidman D, et al. Impact of parity on obstetric and neonatal outcome of external cephalic version. J Obstet Gynaecol 2007; 27:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/25\">",
"      Agrawal S, Agarwal A, Das V. Impact of grandmultiparity on obstetric outcome in low resource setting. J Obstet Gynaecol Res 2011; 37:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/26\">",
"      Shechter Y, Levy A, Wiznitzer A, et al. Obstetric complications in grand and great grand multiparous women. J Matern Fetal Neonatal Med 2010; 23:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/27\">",
"      Shah PS, Knowledge Synthesis Group on Determinants of LBW/PT births. Parity and low birth weight and preterm birth: a systematic review and meta-analyses. Acta Obstet Gynecol Scand 2010; 89:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/28\">",
"      Jacquemyn Y, Senten L, Vellinga S, et al. Does practice make perfect? An age-matched study on grand multiparity in Flanders, Belgium. J Perinat Med 2006; 34:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/29\">",
"      Hilder L, Sairam S, Thilaganathan B. Influence of parity on fetal mortality in prolonged pregnancy. Eur J Obstet Gynecol Reprod Biol 2007; 132:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17556/abstract/30\">",
"      Geidam AD, Audu BM, Oummate Z. Pregnancy outcome among grand multiparous women at the University of Maiduguri Teaching Hospital: a case control study. J Obstet Gynaecol 2011; 31:404.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 436 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17556=[""].join("\n");
var outline_f17_9_17556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VARIABLES AFFECTING THE RELATIONSHIP BETWEEN PARITY AND PREGNANCY OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Variability in the definition of parity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Variability in the definition of controls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonlinear relationship between parity and pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inadequate adjustment for maternal age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Healthy person effect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREGNANCY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_9_17557="Cerebral veins and sinuses";
var content_f17_9_17557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Major cerebral veins and sinuses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 609px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17557=[""].join("\n");
var outline_f17_9_17557=null;
var title_f17_9_17558="Isolated limb infusion";
var content_f17_9_17558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Isolated limb infusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 701px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn with permission from: Brady MS, Brown K, Patel A, et al. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res 2009; 19:106. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17558=[""].join("\n");
var outline_f17_9_17558=null;
var title_f17_9_17559="Dexmethylphenidate: Pediatric drug information";
var content_f17_9_17559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexmethylphenidate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?22/44/23238?source=see_link\">",
"    see \"Dexmethylphenidate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/14/44261?source=see_link\">",
"    see \"Dexmethylphenidate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Focalin XR&reg;;",
"     </li>",
"     <li>",
"      Focalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1008289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Central Nervous System Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1008319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/44/23238?source=see_link\">",
"      see \"Dexmethylphenidate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reduce dose or discontinue in patients with paradoxical aggravation of symptoms or other adverse events. Discontinue if no improvement is seen after appropriate dosage adjustment over a 1-month period of time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"     Children &ge;6 years and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Patients not currently taking methylphenidate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Immediate release: Initial: 2.5 mg twice daily; doses should be taken at least 4 hours apart; dosage may be adjusted in increments of 2.5-5 mg at weekly intervals; maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     (manufacturer labeling); some experts recommend maximum daily dose: 50 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Extended release: Initial: 5 mg once daily; dosage may be adjusted in increments of 5 mg/day at weekly intervals; maximum daily dose: 30 mg/",
"     <b>",
"      day",
"     </b>",
"     (manufacturer labeling); some experts recommend maximum daily dose: 50 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Conversion to dexmethylphenidate from methylphenidate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Immediate release: Initial: Half the total daily dose of racemic methylphenidate; maximum daily dexmethylphenidate dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     (manufacturer labeling); some experts recommend maximum daily dose: 50 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Extended release: Initial: Half the total daily dose of racemic methylphenidate; maximum daily dexmethylphenidate dose: 30 mg/",
"     <b>",
"      day",
"     </b>",
"     (manufacturer labeling); some experts recommend maximum daily dose: 50 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Conversion from dexmethylphenidate immediate release to dexmethylphenidate extended release:",
"     </b>",
"     When changing from Focalin&reg; tablets to Focalin&reg; XR capsules, switch to the same daily dose using Focalin&reg; XR; maximum daily dose: 30 mg/",
"     <b>",
"      day",
"     </b>",
"     (manufacturer labeling); some experts recommend maximum daily dose: 50 mg/",
"     <b>",
"      day",
"     </b>",
"     (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Patients not currently taking methylphenidate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release: Initial: 2.5 mg twice daily; dosage may be adjusted in increments of 2.5-5 mg at weekly intervals; maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; doses should be taken at least 4 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release: Initial: 10 mg once daily; dosage may be adjusted in increments of 10 mg/",
"     <b>",
"      day",
"     </b>",
"     at weekly intervals; maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Conversion to dexmethylphenidate from methylphenidate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release: Initial: Half the total daily dose of racemic methylphenidate; maximum daily dexmethylphenidate dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release: Initial: Half the total daily dose of racemic methylphenidate; maximum daily dexmethylphenidate dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Conversion from dexmethylphenidate immediate release to dexmethylphenidate extended release:",
"     </b>",
"     When changing from Focalin&reg; tablets to Focalin&reg; XR capsules, switch to the same daily dose using Focalin&reg; XR; maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustments provided in the manufacturer's labeling; however, since very little unchanged drug is eliminated in the urine, dosage adjustment in renal impairment is not expected to be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustments provided in the manufacturer's labeling (not studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Focalin XR&reg;: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg [bimodal release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Focalin&reg;: 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Focalin&reg;: 10 mg [dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F158431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Focalin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088600.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088600.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Focalin&reg; XR:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088601.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088601.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1008323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Twice daily dosing should be administered at least 4 hours apart; may be taken with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Administer once daily in the morning. Do not crush, chew, or divide capsule; swallow whole. Capsule may be opened and contents sprinkled over a spoonful of applesauce; consume immediately and entirely; do not store for future use.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1008307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release capsule: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Dispense in tight container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1008290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5707763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexmethylphenidate may be confused with methadone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Focalin&reg; may be confused with Folotyn&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F158434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression (children), dizziness (adults), fever (children), headache, insomnia (children), irritability (children), mood swings (children), restlessness (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (children), anorexia (children), appetite decreased (children), dyspepsia, nausea (children), pharyngolaryngeal pain (adults), vomiting (children), xerostomia (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Accommodation difficulties, anaphylaxis, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Also refer to Methylphenidate for adverse effects seen with other methylphenidate products.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1008294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexmethylphenidate, methylphenidate, or any component; glaucoma; motor tics; Tourette's syndrome (diagnosis or family history); patients with marked agitation, tension, and anxiety; concurrent use or use within 14 days of MAO inhibitors (hypertensive crisis may occur)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4994511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with heart failure, recent MI, hyperthyroidism, acute stress reactions, emotional instability. Hematological monitoring is advised with long-term use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1008295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Serious cardiovascular events including sudden death may occur in patients with pre-existing structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of CNS stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of a stimulant drug. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. The American  Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as dexmethylphenidate, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered.",
"     <b>",
"      Note:",
"     </b>",
"     ECG abnormalities and four cases of sudden cardiac death have been reported in children receiving clonidine with methylphenidate; this problem may potentially occur with dexmethylphenidate; consider ECG monitoring and reduction of dexmethylphenidate dose when used concurrently with clonidine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould, 2009). In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2-24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31-1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57-1.89) users compared to nonusers. It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low (Cooper, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Stimulant medications may increase blood pressure (average increase 2-4 mm Hg) and heart rate (average increase 3-6 bpm); some patients may experience greater increases; use stimulant medications with caution in patients with hypertension and other cardiovascular conditions that may be exacerbated by increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Psychiatric  adverse events may occur. Stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychosis. New-onset psychosis or mania may occur with stimulant use in patients without a prior history of psychotic illness or mania, even at standard doses. Stimulants may induce mixed/manic episodes in patients with bipolar disorder; patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Long-term effects in pediatric patients have not been determined. Use of stimulants in children has been associated with growth suppression; monitor growth; treatment interruption may be needed. Appetite suppression may occur; monitor weight during therapy, particularly in children. Stimulants may lower seizure threshold leading to new onset or breakthrough seizure activity; use with caution in patients with a history of seizure disorder. Visual disturbances, such as difficulty in accommodation and blurred vision, have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     CNS stimulants possess a high potential for abuse",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; misuse may cause sudden death and serious cardiovascular adverse events; prolonged administration may lead to drug dependence; abrupt discontinuation following high doses or for prolonged periods may result in symptoms of withdrawal; avoid abrupt discontinuation in patients who have received dexmethylphenidate for prolonged periods; use with caution in patients with history of ethanol or drug abuse. Do not use for severe depression or normal fatigue states.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Hypersensitivity reactions (angioedema and anaphylactic reactions) have been reported with methylphenidate; similar reactions could occur with dexmethylphenidate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Dexmethylphenidate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Dexmethylphenidate may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Dexmethylphenidate may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Dexmethylphenidate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Dexmethylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Dexmethylphenidate may increase the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Dexmethylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Dexmethylphenidate may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1008306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release tablets: A high-fat meal delays the time to peak concentration, but not the extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release capsules: Effect of food has not been studied. Based on studies of the same type of extended release formulation of racemic methylphenidate, a high-fat meal may decrease the time to peak concentration, but not the extent of absorption. Administration with applesauce should not affect the plasma concentration-time profile.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit to the mother outweighs the possible risks to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1008325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CNS activity; CBC with differential, platelet count; blood pressure and heart rate (baseline following dose increases and periodically during treatment),  sleep, appetite, abnormal movements, height, weight, BMI, growth in children. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, or depression. Monitor for visual disturbances.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1008309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dexmethylphenidate is the more active,",
"     <i>",
"      d-threo",
"     </i>",
"     -enantiomer, of racemic methylphenidate. It is a CNS stimulant; blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, thus increasing the concentrations of these neurotransmitters in the extraneuronal space. It also inhibits monoamine oxidase which is responsible for the breakdown of neurotransmitters norepinephrine and dopamine.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4994512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Rapid, within 1-2 hours of an effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Immediate release: 3-5 hours; extended release: 9-12 hours (Dopheide, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1008311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release: Rapid; Extended release: Bimodal (with 2 peak concentrations ~4 hours apart)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.65 &plusmn; 1.11 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Unknown; racemic methylphenidate: 12% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via de-esterification to inactive metabolite,",
"     <i>",
"      d",
"     </i>",
"     -&alpha;-phenyl-piperidine acetic acid (",
"     <i>",
"      d",
"     </i>",
"     -ritalinic acid)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 22% to 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-4.5 hours;",
"     <b>",
"      Note:",
"     </b>",
"     A few subjects displayed a half-life between 5-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Immediate release: Fasting: 1-1.5 hours; after a high-fat meal: 2.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Extended release: First peak: 1.5 hours (range: 1-4 hours); second peak: 6.5 hours (range: 4.5-7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (90%, primarily as inactive metabolite)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1008328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/14/44261?source=see_link\">",
"      see \"Dexmethylphenidate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of dexmethylphenidate. Serious cardiac effects or psychiatric adverse effects may occur; notify  physician of any heart problems, high blood pressure, or psychiatric conditions before starting therapy. May reduce the growth rate in children and has been associated with worsening of aggressive behavior; notify physician if child displays aggression or hostility;  ensure  that physician monitors weight and height. Avoid caffeine and the herbal medicine St John's wort. May be habit-forming; avoid abrupt discontinuation after prolonged use. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Notify physician if blurred vision occurs. Report the use of other medications and herbal or natural products.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1008329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment with dexmethylphenidate should include &ldquo;drug holidays&rdquo; or periodic discontinuation in order to assess the patient's requirements, decrease tolerance, and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures. Long-term use of the immediate release tablets (ie, &gt;6 weeks) and extended release capsules (&gt;7 weeks) has not been studied; long-term usefulness should be periodically re-evaluated for the individual patient.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Focalin&reg; XR capsules use a bimodal release where",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the dose is provided in immediate release beads and",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the dose is in delayed release beads. A single, once-daily dose of a capsule provides the same amount of dexmethylphenidate as two tablets given 4 hours apart. The modified release properties of Focalin&reg; XR capsules are pH dependent; thus, concomitant administration of antacids or acid suppressants might alter the release of dexmethylphenidate.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, \"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 128(5):1007-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroon.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, \"ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA and Pliszka SR, \"Attention-Deficit-Hyperactivity Disorder: An Update,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(6):656-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/19476419/pubmed\" id=\"19476419\" target=\"_blank\">",
"        19476419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gelperin K, \"Cardiovascular Risk With Drug Treatments of ADHD,\" available at: file://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4210s-index.htm. Accessed May 25, 2006.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gelperin K, \"Psychiatric Adverse Events With Drug Treatments of ADHD,\" available at: file://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4210s-index.htm. Accessed May 25, 2006.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MS, Walsh BT, Munfakh JL, et al, \"Sudden Death and Use of Stimulant Medications in Youths,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2009, 166(9):992-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/19528194/pubmed\" id=\"19528194\" target=\"_blank\">",
"        19528194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenhill LL, Muniz R, Ball RR, et al, \"Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2006, 45(7):817-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/16832318/pubmed\" id=\"16832318\" target=\"_blank\">",
"        16832318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-Up: Changes in Effectiveness and Growth After the End of Treatment,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 113(4):762-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/15060225/pubmed\" id=\"15060225\" target=\"_blank\">",
"        15060225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, &ldquo;ADHD Drugs and Cardiovascular Risk,&rdquo;",
"      <i>",
"       New Eng J Med",
"      </i>",
"      , 2006, 354(14):1445-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/16549404/pubmed\" id=\"16549404\" target=\"_blank\">",
"        16549404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S and AACAP Work Group on Quality Issues, \"Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poulton A, \"Growth on Stimulant Medication; Clarifying the Confusion: A Review,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2005, 90(8):801-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/16040876/pubmed\" id=\"16040876\" target=\"_blank\">",
"        16040876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prince JB, \"Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Children and Adolescents: Update on New Stimulant Preparations, Atomoxetine, and Novel Treatments,\"",
"      <i>",
"       Child Adolesc Psych Clin N Am",
"      </i>",
"      , 2006, 15(1):13-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/16321724/pubmed\" id=\"16321724\" target=\"_blank\">",
"        16321724",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson DM and Keating GM, \"Dexmethylphenidate Extended Release: In Attention-Deficit Hyperactivity Disorder,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2006, 66(5):661-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/16620143/pubmed\" id=\"16620143\" target=\"_blank\">",
"        16620143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silva RR, Muniz R, Pestreich L, et al, \"Dexmethylphenidate Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2008, 47(2):199-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/18176337/pubmed\" id=\"18176337\" target=\"_blank\">",
"        18176337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silva RR, Muniz R, Pestreich L, et al, \"Efficacy and Duration of Effect of Extended-Release Dexmethylphenidate Versus Placebo in Schoolchildren With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(3):239-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/16768632/pubmed\" id=\"16768632\" target=\"_blank\">",
"        16768632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilens TE, \"Mechanism of Action of Agents Used in Attention-deficit Hyperactivity Disorder,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2006, 67(suppl 8):32-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/9/17559/abstract-text/16961428/pubmed\" id=\"16961428\" target=\"_blank\">",
"        16961428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13010 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17559=[""].join("\n");
var outline_f17_9_17559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708694\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158416\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008289\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008319\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158399\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158384\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158431\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874426\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008323\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008307\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008290\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5707763\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158434\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008294\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4994511\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008295\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299158\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158392\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008306\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158394\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158405\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008325\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008309\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4994512\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008311\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008328\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1008329\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13010\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13010|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/44/23238?source=related_link\">",
"      Dexmethylphenidate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/14/44261?source=related_link\">",
"      Dexmethylphenidate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_9_17560="Histology case 1 with answer";
var content_f17_9_17560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Histology case 1 with answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The correct answer is A. The light micrograph shown in panel A reveals a diffuse",
"    <strong>",
"     proliferative glomerulonephritis",
"    </strong>",
"    , a finding consistent with the clinical presentation of acute nephritis. Panel B shows a focal segmental glomerulosclerosis without hypercellularity, a lesion associated with proteinuria but unlikely to be associated with a nephritic presentation and renal insufficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17560=[""].join("\n");
var outline_f17_9_17560=null;
var title_f17_9_17561="Approach to chronic cough in children";
var content_f17_9_17561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to chronic cough in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17561/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17561/contributors\">",
"     Roni Grad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17561/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17561/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17561/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/9/17561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coughing is an important defensive reflex that protects from aspiration of foreign materials, and enhances clearance of secretions and particulates from the airways. Healthy children may cough on a daily basis; one study documented an average of 11 cough episodes every 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/1\">",
"     1",
"    </a>",
"    ]. However, a cough may also be the presenting symptom of a serious underlying pulmonary or extrapulmonary disease. The causes of chronic cough in children are quite different from that of adults, so evaluation and management of children should not be based on adult protocols. Adolescents 15 years and older may be evaluated using guidelines for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"     \"Evaluation of subacute and chronic cough in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of chronic cough in children includes subacute and chronic infections (eg, bacterial bronchitis, pertussis, mycoplasma, and tuberculosis), foreign body aspiration, and cough-dominant asthma (",
"    <a class=\"graphic graphic_table graphicRef75720 \" href=\"UTD.htm?17/23/17789\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/3\">",
"     3",
"    </a>",
"    ]. Gastroesophageal reflux, upper airway cough syndrome (formerly known as postnasal drip syndrome), and sinusitis are sometimes implicated because of associations with chronic cough in adults, but their role in causing chronic cough in children is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/2\">",
"     2",
"    </a>",
"    ]. Less common disorders must be excluded if the cough is unusually severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent, or when there is evidence of failure to thrive, growth retardation, purulent sputum, exertional dyspnea, hypoxemia, chest pain, or hemoptysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link\">",
"     \"Causes of chronic cough in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An approach to the diagnosis and management of chronic cough in children is presented here. Approaches to wheezing and stridor in children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"     \"Wheezing illnesses other than asthma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies of cough in children have been hampered by the variable definitions used for defining chronicity, the presence of other concomitant symptoms (eg, wheezing), the lack of widely accepted objective clinical endpoints to measure cough severity, and the tendency for cough to resolve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, chronic cough appears to be common, with an estimated prevalence of 5 to 7 percent in preschoolers, and 12 to 15 percent in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Cough is more common among boys than girls up to 11 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/6\">",
"     6",
"    </a>",
"    ], and may be less common in developing countries than in affluent countries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus as to the length of time in the definition of chronic cough in children. The American College of Chest Physicians, Thoracic Society of Australia and New Zealand, and many studies have defined chronic cough as one that lasts more than four weeks, because most acute respiratory infections in children resolve within this interval [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. In comparison, guidelines from the British Thoracic Society define chronic cough as one that lasts more than eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/10\">",
"     10",
"    </a>",
"    ]. However, these guidelines also describe a \"prolonged acute cough\" as one that lasts at least three weeks and is \"relentlessly progressive\"; this type of cough may warrant investigation before eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each cough occurs through the stimulation of a complex reflex arc (",
"    <a class=\"graphic graphic_figure graphicRef55232 \" href=\"UTD.htm?33/15/34046\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. This is initiated by the irritation of cough receptors that exist not only in the epithelium of the upper and lower respiratory tracts, but also in the pericardium, esophagus, diaphragm, stomach, and external ear [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemical receptors sensitive to acid, heat, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/31/24053?source=see_link\">",
"     capsaicin",
"    </a>",
"    -like compounds trigger the cough reflex via activation of the type 1 vanilloid (capsaicin) receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, mechanical cough receptors can be triggered by touch or displacement. The proximal airways (larynx and trachea) are more sensitive to mechanical stimulation, and the distal airways more sensitive to chemical stimulation. Irritation at the bronchiolar and alveolar level does not cause cough.",
"   </p>",
"   <p>",
"    Impulses from stimulated cough receptors traverse afferent branches of the vagus nerve to a \"cough center\" in the medulla and nucleus tractus solitarius, which itself is under control by higher cortical centers. The cough center generates an efferent signal that travels down the vagus, phrenic, and spinal motor nerves to expiratory musculature to produce the cough (",
"    <a class=\"graphic graphic_figure graphicRef55232 \" href=\"UTD.htm?33/15/34046\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. The pelvic sphincter muscles are also stimulated to contract, avoiding urinary incontinence.",
"   </p>",
"   <p>",
"    The mechanical events of a cough can be divided into three phases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspiratory phase: Inhalation, which generates the volume necessary for an effective cough.",
"     </li>",
"     <li>",
"      Compression phase: Closure of the larynx combined with contraction of muscles of chest wall, diaphragm, and abdominal wall result in a rapid rise in intrathoracic pressure.",
"     </li>",
"     <li>",
"      Expiratory phase: The glottis opens, resulting in high expiratory airflow and the coughing sound. Large airway compression occurs. The high flows dislodge mucus from the airways and allow removal from the tracheobronchial tree.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific pattern of the cough depends on the site and type of stimulation. Mechanical laryngeal stimulation results in immediate expiratory stimulation (sometimes termed the expiratory reflex), probably to protect the airway from aspiration; stimulation distal to the larynx causes a more prominent inspiratory phase, presumably to generate the airflow necessary to remove the stimulus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ineffective cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough is an important defensive reflex that is required to maintain the health of the lungs. Children who do not cough effectively are at risk for atelectasis, recurrent pneumonia, and chronic airways disease from aspiration and retention of secretions. Many disorders can impair a child's ability to cough effectively, resulting in persistent cough. Children with neuromuscular disease and chest wall deformities may not generate a deep enough inspiratory volume or expiratory flow necessary for effective clearance of secretions due to defective \"pump\" mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/16\">",
"     16",
"    </a>",
"    ]. Children with reduced function of the abdominal wall musculature are particularly at risk for ineffective cough. Children with tracheo-bronchomalacia (\"floppy\" airways), or with obstructive airways diseases, often do not generate the high flow rates needed for effective clearance of secretions. Individuals with laryngeal disorders, including those with tracheostomies, may not achieve sufficient laryngeal closure to generate the increased intrathoracic pressures necessary for an effective cough [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach outlined in this topic review assumes a definition of chronic cough that has lasted at least four weeks. Some presenting symptoms warrant earlier evaluation (eg, onset after an episode of choking, suggesting foreign body aspiration).",
"   </p>",
"   <p>",
"    Children with chronic cough should be evaluated with a detailed history, physical examination, chest radiograph, and (if the child is able) spirometry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/2,3,5,7\">",
"     2,3,5,7",
"    </a>",
"    ]. This evaluation often provides sufficient information to categorize the cough as specific (ie, caused by an underlying disease) or nonspecific (no evidence of an underlying disease).",
"   </p>",
"   <p>",
"    Further evaluation depends on the provisional diagnosis and the course of the symptoms (",
"    <a class=\"graphic graphic_algorithm graphicRef74085 \" href=\"UTD.htm?23/57/24471\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Specific cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of specific chronic cough fall into the following general categories (",
"    <a class=\"graphic graphic_table graphicRef75873 \" href=\"UTD.htm?17/57/18333\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Persistent bacterial bronchitis",
"     </li>",
"     <li>",
"      Chronic suppurative lung disease and bronchiectasis",
"     </li>",
"     <li>",
"      Airway abnormality (congenital, foreign body, or neoplastic)",
"     </li>",
"     <li>",
"      Aspiration",
"     </li>",
"     <li>",
"      Chronic or less common infections",
"     </li>",
"     <li>",
"      Interstitial lung disease",
"     </li>",
"     <li>",
"      Extrapulmonary causes: cardiac abnormalities, ear conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sequence of evaluation for these disorders is informed by the age and presenting features of the child. Identification of the presenting features and cough characteristics is important because many are easily recognizable and strongly suggestive of a specific cause; this is less true in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link\">",
"     \"Causes of chronic cough in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Key symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain symptoms and signs are highly predictive of a specific cough. These signs or symptoms narrow the diagnostic possibilities and call for further specific testing or referral (",
"    <a class=\"graphic graphic_algorithm graphicRef74085 \" href=\"UTD.htm?23/57/24471\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic wet cough",
"     </li>",
"     <li>",
"      Wheezing or crepitations",
"     </li>",
"     <li>",
"      Onset after an episode of choking, or sudden onset while eating or playing",
"     </li>",
"     <li>",
"      Abnormal chest radiography or spirometry",
"     </li>",
"     <li>",
"      Associated cardiac or neurologic abnormalities",
"     </li>",
"     <li>",
"      Failure to thrive, feeding difficulties, or hemoptysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In particular, the symptom of a chronic wet cough, with or without production of purulent sputum, is always pathologic and warrants investigations for a persistent endobronchial infection (persistent bacterial bronchitis or chronic suppurative lung disease), retained airway foreign body, or immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of chronic cough in children\", section on 'Specific cough'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nonspecific cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;If symptoms suggesting specific cough are absent and the chest radiograph and spirometry are normal, a presumptive diagnosis of nonspecific cough should be made (",
"    <a class=\"graphic graphic_algorithm graphicRef74085 \" href=\"UTD.htm?23/57/24471\">",
"     algorithm 1",
"    </a>",
"    ). If the cough is troublesome, the possibility of asthma should be considered and pursued with an empiric trial of bronchodilators and other asthma medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of chronic cough in children\", section on 'Asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is no response, the child should be considered to have a nonspecific cough, and the medication should be stopped. The child and parents should be reassured and the patient observed over time for possible emergence of specific symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach outlined above requires a detailed history, which should focus on the following key elements:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Age and circumstances at onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal onset of coughing should prompt consideration of congenital malformations (eg, tracheobronchomalacia), conditions predisposing to aspiration (eg, tracheoesophageal fistula, laryngeal cleft, or a neurological disorder), or chronic pulmonary infections (eg, cystic fibrosis or ciliary dyskinesia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A cough that begins suddenly while playing or eating, especially in the toddler age range, should raise suspicion of an aspirated foreign body in the airway. The physician should specifically ask about a history of choking, because this may have occurred weeks before and the family may not voluntarily recall the information. Even if there is no history of choking, a foreign body remains a diagnostic possibility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An episode of severe pneumonia can damage the airways, making the child vulnerable to chronic cough. More rarely, severe pneumonia may cause frank bronchiectasis. A psychogenic or habitual cough also often begins after an upper respiratory infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nature of the cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic paroxysmal cough triggered by exercise, cold air, sleep, or allergens is often seen in patients with asthma. Barking or brassy cough suggests a process in the trachea or more proximal airways, such as airway malacia, laryngotracheobronchitis, spasmodic croup, or foreign body. Staccato cough in young infants can be the result of infection with Chlamydia trachomatis. Cough that is honking (\"Canadian Goose-like\") and disappears at night suggests a psychogenic or habitual cough.",
"   </p>",
"   <p>",
"    A chronic productive (or \"wet-moist\") cough suggests a suppurative process, and may require further investigation to exclude bronchiectasis, cystic fibrosis, active infection, immune deficiency, or congenital malformation. In a study of children presenting with chronic cough, a wet-moist quality to the cough was the most useful clinical marker of predicting a specific etiology (sensitivity of 96 percent, although specificity was only 26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/17\">",
"     17",
"    </a>",
"    ]. Specific causes of chronic wet-moist cough include bacterial bronchitis (40 percent of young children with wet cough in one series), bronchiectasis, asthma-like conditions, and aspiration disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Specific cough'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Acute or subacute paroxysmal cough suggests infection with pertussis or parapertussis; this characteristic cough can be retriggered by subsequent upper respiratory illness. An inspiratory \"whoop\", when present, is an important diagnostic clue. The diagnosis can be difficult to ascertain, as cultures are typically negative after the fourth week of illness, and convalescent-phase serology can be difficult to interpret unless acute-phase titers were also obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Timing and triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing and triggers associated with cough can help guide diagnosis. Cough due to asthma typically occurs following exposure to characteristic asthma triggers (ie, allergens, smoke, exercise, cold air, or viral infection), and typically worsens during sleep. Cough associated with nasal problems typically is worst during changes of position, while cough due to bronchiectasis typically is worst and most productive early in the day.",
"   </p>",
"   <p>",
"    Cough that is triggered during swallowing is suggestive of aspiration, either primary or due to tracheoesophageal fistula or laryngeal abnormalities. Cough in the first hour after meals, or which is worse while supine, may reflect gastroesophageal reflux. Psychogenic cough is present during the day, disappears at night, and is typically worst and most disruptive during school classes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=see_link\">",
"     \"Congenital anomalies of the larynx\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of dyspnea or hemoptysis should trigger a search for an underlying lung disease. Hemoptysis should also raise concerns of bronchiectasis, cavitary lung disease (tuberculosis or bacterial abscesses), heart failure, hemosiderosis, neoplasm, foreign bodies, vascular lesions, endobronchial lesions, catamenial bleeding, and clotting disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37896?source=see_link\">",
"     \"Hemoptysis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cough, with or without symptoms of pancreatic insufficiency, recurrent endobronchial infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure to thrive should raise suspicion of cystic fibrosis. Cough associated with persistent fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure to thrive, or weight loss should raise suspicion of chronic infection and immune deficiency. Children with neurologic impairment or seizures frequently have chronic aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anaphylactic reactions to food can include cough but are unlikely to present with recurrent cough in the absence of other symptoms of anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link&amp;anchor=H14#H14\">",
"     \"Food-induced anaphylaxis\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The past medical history should include an account of the pregnancy, labor, and delivery, as well as the neonatal course. Low birth weight",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    premature neonates are at risk for developing atopic sensitization and asthma. In addition, prematurity and neonatal respiratory distress syndrome are precursors for bronchopulmonary dysplasia, which may cause persistent respiratory symptoms in children and adolescents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H26#H26\">",
"     \"Risk factors for asthma\", section on 'Pre- and perinatal factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The past medical history should also include questions related to eczema and pulmonary infections. In preschool children, a history of infantile eczema is often associated with inhalant allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/20\">",
"     20",
"    </a>",
"    ]. Coughing episodes diagnosed as pneumonia may or may not have been related to other pulmonary processes, as discussed below.",
"   </p>",
"   <p>",
"    Recurrent right middle lobe atelectasis or infiltrates are common in children with asthma and other processes that cause increased mucus production, due to relatively poor collateral ventilation in the right middle lobe. This is frequently mistaken for pneumonia. A history of recurrent or unresolving pneumonia in one lobe or segment of the lung may also be caused by obstruction or anatomic abnormality in that airway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with chronic cough and a history of recurrent pneumonias involving multiple lobes, considerations include cystic fibrosis, immune deficiency, aspiration (swallowing dysfunction, gastroesophageal reflux, tracheoesophageal fistula), primary ciliary dyskinesia, immune deficiency and autoimmune disease. Severe infection caused by pertussis or adenovirus has been associated with the subsequent development of bronchiectasis, bronchiolitis obliterans, and chronic lung disease. If the child is known to be immunodeficient, atypical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic infections of the sinuses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lungs should be suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family history of atopy or asthma increases the risk in offspring, and suggests a diagnosis of either allergic rhinitis or asthma in the child with chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Family history of cystic fibrosis or primary ciliary dyskinesia should raise suspicion for these disorders. A careful history should be obtained for current illness in family members or close contacts; such individuals with cough, weight loss, and night sweats should arouse suspicion of tuberculosis. In some cases, the possibility of HIV transmission from mother to child should be assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Social history and environmental exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive or active exposure to smoke from tobacco [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/20\">",
"     20",
"    </a>",
"    ], marijuana, cocaine or other chemical irritants can result in chronic cough. Indoors, damp homes are associated with chronic respiratory complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, wood-burning stoves cause indoor air pollution and can predispose children to respiratory infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/23\">",
"     23",
"    </a>",
"    ]. Gas stoves are also associated with respiratory symptoms in children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/24\">",
"     24",
"    </a>",
"    ]. These environmental exposures are important exacerbating factors for chronic cough in some children but are not necessarily the sole causative factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Residence in the inner cities of the United States is associated with exposure to cockroaches and mice, which are common allergens in these environments [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Outdoor air pollution in inner cities is also associated with chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Indoor air pollution due to the use of biomass fuels (wood and crop residues and animal dung) is common in developing countries; this may predispose children to respiratory infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to elicit any history of contact with pets or other animals, as cough may be induced by allergy to the animals. Similarly, the location of the child's home and travel history may be relevant. Local epidemiology can inform the diagnostic considerations, especially with respect to endemic fungal and parasitic infections (",
"    <a class=\"graphic graphic_table graphicRef53572 \" href=\"UTD.htm?15/20/15692\">",
"     table 3",
"    </a>",
"    ). Histoplasmosis is commonly associated with exposure to birds and bats, and echinococcosis with exposure to dogs and sheep. Residents of the Southwestern United States, Northern Mexico, and parts of Central and South America are at risk for coccidiomycosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28025?source=see_link\">",
"     \"Clinical manifestations and diagnosis of echinococcosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The symptom of chronic cough is a source of stress and concern for patients and their families. Acknowledging this and other sources of stress may facilitate communication and appropriate counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to prior therapy may yield some diagnostic clues regarding the cause of chronic cough. Previous response to antihistamines suggests a component of rhinitis and postnasal drip, while a response to inhaled bronchodilators suggests possible asthma. However, any prior response to medication needs to be interpreted with great caution, since symptoms can spontaneously remit. Previous response to antibiotics and asthma therapies should be interpreted with special caution, as antibiotics are frequently prescribed for self-limited viral illnesses, and the cough may have resolved spontaneously regardless of treatment.",
"   </p>",
"   <p>",
"    Any medications taken by the patient should be reviewed carefully; angiotensin converting enzyme (ACE) inhibitors are a well-established cause of chronic cough. Patients previously treated with cytotoxic drugs or thoracic radiation are at risk of interstitial lung disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should pay close attention to the following signs of chronic underlying disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General appearance of chronic illness",
"     </li>",
"     <li>",
"      Poor growth, thinness, or obesity",
"     </li>",
"     <li>",
"      Increased work of breathing, retractions, accessory muscle use, chest wall hyperinflation or deformity, abnormal breath sounds (reduced intensity, asymmetry, wheezing, stridor, crackles)",
"     </li>",
"     <li>",
"      Shiners, swollen nasal turbinates, nasal obstruction, nasal polyps, allergic nasal crease, halitosis, tonsillar hypertrophy, pharyngeal cobblestoning, high arched or cleft palate, hoarseness",
"     </li>",
"     <li>",
"      Tympanic membrane scarring or frank otorrhea",
"     </li>",
"     <li>",
"      Abnormal heart sounds, abnormal pulses",
"     </li>",
"     <li>",
"      Hepato-",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      splenomegaly, abdominal masses, bloating, rectal prolapse",
"     </li>",
"     <li>",
"      Edema of the extremities, cyanosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clubbing of the digits",
"     </li>",
"     <li>",
"      Rashes and other skin lesions (eg, scars of healed recurrent impetigo)",
"     </li>",
"     <li>",
"      Neurologic abnormalities",
"     </li>",
"     <li>",
"      Dysmorphism or other evidence of a genetic syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chest examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristics of the cough should be observed, first if it occurs spontaneously during the interview, and if not, then during a voluntary cough maneuver. These characteristics are an important factor in determining the diagnostic approach. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnostic approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Chronic cough and wheeze are often noted in combination. Even in the absence of a history of wheeze, clinicians should pay close attention to any evidence of this finding on physical examination.",
"   </p>",
"   <p>",
"    Polyphonic wheezing (ie, many different pitches) with cough is typical of asthma; the wheezing occurs on expiration and sometimes also on inspiration. Many children with asthma are also atopic and exhibit signs of rhinitis, conjunctivitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eczema [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/21\">",
"     21",
"    </a>",
"    ]. Other causes of polyphonic wheezing include viral bronchiolitis, obliterative bronchiolitis, bronchiectasis (cystic fibrosis, allergic bronchopulmonary aspergillosis, primary ciliary dyskinesia), bronchopulmonary dysplasia, heart failure, immunodeficiency, bronchomalacia, and aspiration syndromes.",
"   </p>",
"   <p>",
"    Monophonic wheezing (a single, distinct noise of one pitch and starting and stopping at one discrete time) and cough should always raise suspicion of large airway obstruction caused by foreign body aspiration or malacia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stenosis of the central airways. The wheeze of large airway obstruction can often be heard without a stethoscope. In addition, vascular rings, lymphadenopathy, and mediastinal tumors can cause extrinsic large airway obstruction. Tuberculosis should always be considered in a child with a monophonic wheeze, particularly in areas where the disease is prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/33\">",
"     33",
"    </a>",
"    ]. In children with tuberculosis, wheezing is probably caused by extrinsic compression of the central airways from contiguous hilar adenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CHEST RADIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a thorough history and physical examination, a chest radiograph should be obtained. If foreign body aspiration is suspected because of the age, clinical presentation or history, frontal films should be obtained during both inspiration and expiration, to evaluate for unilateral lung hyperinflation that would suggest airway obstruction. Similar information can be obtained from the combination of frontal, right lateral decubitus, and left lateral decubitus radiographs.",
"   </p>",
"   <p>",
"    A definitive diagnosis is rarely made on the radiographic findings alone, but the following radiographic appearances lend some support to specific diagnoses, and may be helpful in determining the sequence of subsequent diagnostic tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal chest radiograph &mdash; This is typical in habit cough. However, patients with a variety of pathological conditions, including foreign body, asthma, early cystic fibrosis, and bronchiectasis, can also have normal chest radiographs.",
"     </li>",
"     <li>",
"      Bilateral peribronchial accentuation (\"cuffing\") with or without hyperinflation &mdash; This finding suggests diffuse airway inflammation or infection, and can be seen in patients with asthma, cystic fibrosis, persistent bacterial bronchitis, chronic aspiration, and primary ciliary dyskinesia.",
"     </li>",
"     <li>",
"      Bilateral peribronchial accentuation with one or more focal consolidated infiltrates &mdash; These findings are also seen with diffuse airway inflammation, including asthma, persistent bacterial bronchitis, or disorders of impaired airway clearance (eg, ciliary dyskinesia and cystic fibrosis). Infiltrates are most commonly seen in the right middle lobe.",
"     </li>",
"     <li>",
"      Asymmetry in aeration or vascular markings &mdash; These findings suggest the possibility of partial airway obstruction, such as from a foreign body, vascular compression, or bronchial stenosis.",
"     </li>",
"     <li>",
"      Right middle lobe infiltrates &mdash; This distribution is frequently seen in patients with obstructive airway disease; it reflects atelectasis and appears in the right middle lobe because the collateral ventilation in this lobe is underdeveloped in comparison to the other lobes.",
"     </li>",
"     <li>",
"      Peribronchial accentuation with associated macronodularity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      linear infiltrates emanating from the hilum &mdash; This appearance is consistent with bronchiectasis. Other findings in bronchiectasis are linear atelectasis, dilated and thickened airways (ie, tram-tracking or parallel lines, ring shadows on cross section) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75583 graphicRef63795 \" href=\"UTD.htm?34/56/35721\">",
"       image 1A-B",
"      </a>",
"      ), and irregular peripheral opacities that may represent mucopurulent plugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link&amp;anchor=H7#H7\">",
"       \"Causes of chronic cough in children\", section on 'Chronic suppurative lung disease and bronchiectasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hilar adenopathy &mdash; This finding raises the possibility of mycobacterial or fungal infection (",
"      <a class=\"graphic graphic_table graphicRef53572 \" href=\"UTD.htm?15/20/15692\">",
"       table 3",
"      </a>",
"      ), sarcoidosis, or tumor.",
"     </li>",
"     <li>",
"      Mediastinal widening &mdash; This finding in children suggests chronic infection, marked lymphadenopathy, or neoplasm. In an infant or young child, the most common cause of mediastinal is a normal thymus (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77395 \" href=\"UTD.htm?13/11/13489\">",
"       image 2",
"      </a>",
"      ). If the structure is not readily identified on plain film, it can be further characterized by ultrasound, computerized tomography, or magnetic resonance imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large or abnormally shaped heart &mdash; This suggests a primary cardiac defect. A large pulmonary artery may be caused by primary or secondary pulmonary hypertension.",
"     </li>",
"     <li>",
"      Abnormalities of the pleura &mdash; Pneumothorax, pleural effusion, and pleural thickening all suggest underlying lung disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PULMONARY FUNCTION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry will show signs of obstruction in diseases that obstruct the airways, and restriction in interstitial or chest wall restrictive processes. Suboptimal effort on the part of the child will also result in a restrictive picture; thus, spirometry should be conducted by a technician proficient in testing children.",
"   </p>",
"   <p>",
"    If an obstructive pattern is seen on the expiratory flow-volume loop, the reversibility of the obstruction can be assessed by measuring FEV1 before and after inhalation of a bronchodilating agent. A positive response to bronchodilators establishes the presence of airway reactivity, and is suggestive of asthma but does not rule out other disorders. As an example, children with cystic fibrosis often respond to bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/36\">",
"     36",
"    </a>",
"    ]. Abnormalities on the inspiratory loop correlate with extrathoracic airway obstruction, more often associated with stridor than cough. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     BRONCHOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary indication for urgent bronchoscopy in children with chronic cough is for suspected foreign body aspiration. This diagnosis should always be considered, even in the absence of obvious findings, especially in younger children",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if there is a history of a choking episode preceding the onset of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchoscopy is also valuable in the evaluation of suspected airway malacia, tracheoesophageal fistula, or stenosis. Patients with presumed infectious etiologies in whom a sputum sample is not obtained or yields negative results can be evaluated with flexible bronchoscopy to perform bronchoalveolar lavage for bacterial, fungal, and mycobacterial cultures. Bronchial brushings can also be taken for patients with suspected ciliary dyskinesia, although nasal brushings also may be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=see_link&amp;anchor=H26740088#H26740088\">",
"     \"Primary ciliary dyskinesia (immotile-cilia syndrome)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional evaluation depends upon the diagnosis (or diagnoses) being considered (",
"    <a class=\"graphic graphic_table graphicRef75873 \" href=\"UTD.htm?17/57/18333\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Esophageal pH monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether gastroesophageal reflux disease (GERD) is an important cause of isolated chronic cough in children is controversial. Most authorities suggest that this is not a common cause except in association with neurologic abnormalities predisposing to aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link&amp;anchor=H9#H9\">",
"     \"Causes of chronic cough in children\", section on 'Gastroesophageal reflux'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with features strongly suggestive of GERD, esophageal pH monitoring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an empiric trial of treatment for GERD may be undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Sinus imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most authorities suggest that sinusitis is not a common cause of chronic cough in children except in association with an immune defect predisposing to chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Historical series in which sinusitis was diagnosed on the basis of response to antibiotics may have included cases of persistent bacterial bronchitis, which would also respond to antibiotics, or patients who would have improved even without antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of chronic cough in children\", section on 'Upper airway cough syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with clinical features strongly suggestive of sinusitis (eg, mucopurulent drainage, chronic nasal obstruction, or facial pain or pressure), imaging of the sinuses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an empiric trial of treatment for sinusitis may be undertaken. However, the results should be interpreted with caution, because there is poor correlation between sinus radiography or computerized tomography and clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17561/abstract/2,38\">",
"     2,38",
"    </a>",
"    ]. Imaging reveals some sinus abnormality in 20 to 80 percent of asymptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H428232143#H428232143\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Radiologic features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Tuberculin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of tuberculosis may be subtle in children. Therefore, tuberculin skin testing should be considered, even in the absence of obvious signs and symptoms, particularly if the child is at high risk for exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=see_link\">",
"     \"Latent tuberculosis infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link\">",
"     \"Tuberculosis disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Allergy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preschool children, skin prick testing or radioallergosorbent testing (RAST) for defining the presence of atopy may be indicated and, when positive, increases the likelihood that the child has asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=see_link\">",
"       \"Patient information: Cough in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no consensus definition of the time frame for chronic cough in children. Chronic cough is often defined as a cough lasting more than four weeks, because most acute respiratory infections in children resolve within this interval. Other schemes define chronic cough as one that last more than eight weeks but also recognize that a relentlessly progressive cough often warrants evaluation prior to eight weeks. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic cough can be a symptom of congenital anomalies, genetic disease, airway obstruction, infection, airway inflammation without infection (as in asthma), neoplasia, or psychogenic processes (",
"      <a class=\"graphic graphic_table graphicRef75720 \" href=\"UTD.htm?17/23/17789\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Specific cough'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link\">",
"       \"Causes of chronic cough in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The evaluation of a child with chronic cough should include a detailed history, physical examination, chest radiograph, and spirometry (when possible). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms and signs that are highly predictive of a specific cough include chronic wet cough, wheezing or crepitations, onset after a choking episode, abnormal chest radiography or spirometry, associated cardiac or neurologic abnormalities, and failure to thrive, feeding difficulties, or hemoptysis. These signs or symptoms narrow the diagnostic possibilities and call for further specific testing or referral (",
"      <a class=\"graphic graphic_algorithm graphicRef74085 \" href=\"UTD.htm?23/57/24471\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Key symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptom of a chronic wet cough in a young child, usually indicates persistent bacterial sinusitis or retained foreign body. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nature of the cough'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link&amp;anchor=H4#H4\">",
"       \"Causes of chronic cough in children\", section on 'Persistent bacterial bronchitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A chronic cough that first began after an episode of choking, or that began suddenly while eating or playing (especially in a preschool-aged child), suggests the possibility of foreign body aspiration. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Age and circumstances at onset'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/1\">",
"      Munyard P, Bush A. How much coughing is normal? Arch Dis Child 1996; 74:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/2\">",
"      Chang AB, Glomb WB, ). Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:260S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/3\">",
"      de Jongste JC, Shields MD. Cough . 2: Chronic cough in children. Thorax 2003; 58:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/4\">",
"      Bush A. Paediatric problems of cough. Pulm Pharmacol Ther 2002; 15:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/5\">",
"      Chang AB, Asher MI. A review of cough in children. J Asthma 2001; 38:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/6\">",
"      Stein RT, Holberg CJ, Sherrill D, et al. Influence of parental smoking on respiratory symptoms during the first decade of life: the Tucson Children's Respiratory Study. Am J Epidemiol 1999; 149:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/7\">",
"      Chang AB, Powell CV. Non-specific cough in children: diagnosis and treatment. Hosp Med 1998; 59:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/8\">",
"      Faniran AO, Peat JK, Woolcock AJ. Measuring persistent cough in children in epidemiological studies: development of a questionnaire and assessment of prevalence in two countries. Chest 1999; 115:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/9\">",
"      Chang AB, Landau LI, Van Asperen PP, et al. Cough in children: definitions and clinical evaluation. Med J Aust 2006; 184:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/10\">",
"      Shields MD, Bush A, Everard ML, et al. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax 2008; 63 Suppl 3:iii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/11\">",
"      Chang AB. Cough, cough receptors, and asthma in children. Pediatr Pulmonol 1999; 28:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/12\">",
"      Widdicombe JG. Sensory neurophysiology of the cough reflex. J Allergy Clin Immunol 1996; 98:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/13\">",
"      Tekdemir I, Aslan A, Elhan A. A clinico-anatomic study of the auricular branch of the vagus nerve and Arnold's ear-cough reflex. Surg Radiol Anat 1998; 20:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/14\">",
"      Morice AH, Geppetti P. Cough. 5: The type 1 vanilloid receptor: a sensory receptor for cough. Thorax 2004; 59:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/15\">",
"      McCool FD. Global physiology and pathophysiology of cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:48S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/16\">",
"      Schramm CM. Current concepts of respiratory complications of neuromuscular disease in children. Curr Opin Pediatr 2000; 12:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/17\">",
"      Marchant JM, Masters IB, Taylor SM, Chang AB. Utility of signs and symptoms of chronic cough in predicting specific cause in children. Thorax 2006; 61:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/18\">",
"      Marchant JM, Masters IB, Taylor SM, et al. Evaluation and outcome of young children with chronic cough. Chest 2006; 129:1132.",
"     </a>",
"    </li>",
"    <li>",
"     Boat TF. Pulmonary hemorrhage and hemoptysis. In: Kendig's Disorders of the Respiratory Tract in Children, 6th, Chernick V, Boat TF (Eds), WB Saunders, Philadelphia 1998. p.623.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/20\">",
"      Eysink PE, Bottema BJ, ter Riet G, et al. Coughing in pre-school children in general practice: when are RAST's for inhalation allergy indicated? Pediatr Allergy Immunol 2004; 15:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/21\">",
"      Castro-Rodr&iacute;guez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/22\">",
"      Austin JB, Russell G. Wheeze, cough, atopy, and indoor environment in the Scottish Highlands. Arch Dis Child 1997; 76:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/23\">",
"      Robin LF, Less PS, Winget M, et al. Wood-burning stoves and lower respiratory illnesses in Navajo children. Pediatr Infect Dis J 1996; 15:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/24\">",
"      Garrett MH, Hooper MA, Hooper BM, Abramson MJ. Respiratory symptoms in children and indoor exposure to nitrogen dioxide and gas stoves. Am J Respir Crit Care Med 1998; 158:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/25\">",
"      Asilsoy S, Bayram E, Agin H, et al. Evaluation of chronic cough in children. Chest 2008; 134:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/26\">",
"      Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997; 336:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/27\">",
"      Phipatanakul W, Eggleston PA, Wright EC, et al. Mouse allergen. II. The relationship of mouse allergen exposure to mouse sensitization and asthma morbidity in inner-city children with asthma. J Allergy Clin Immunol 2000; 106:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/28\">",
"      Hirsch T, Weiland SK, von Mutius E, et al. Inner city air pollution and respiratory health and atopy in children. Eur Respir J 1999; 14:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/29\">",
"      Nicolai T. Air pollution and respiratory disease in children: what is the clinically relevant impact? Pediatr Pulmonol Suppl 1999; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/30\">",
"      Schwartz J. Air pollution and children's health. Pediatrics 2004; 113:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/31\">",
"      Smith KR, Samet JM, Romieu I, Bruce N. Indoor air pollution in developing countries and acute lower respiratory infections in children. Thorax 2000; 55:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/32\">",
"      Marchant JM, Newcombe PA, Juniper EF, et al. What is the burden of chronic cough for families? Chest 2008; 134:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/33\">",
"      Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/34\">",
"      Meza MP, Benson M, Slovis TL. Imaging of mediastinal masses in children. Radiol Clin North Am 1993; 31:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/35\">",
"      Carty H. Ultrasound of the normal thymus in the infant: a simple method of resolving a clinical dilemma. Br J Radiol 1990; 63:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/36\">",
"      Weinberger M. Airways reactivity in patients with CF. Clin Rev Allergy Immunol 2002; 23:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/37\">",
"      Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. Eur Respir J 2004; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17561/abstract/38\">",
"      Shopfner CE, Rossi JO. Roentgen evaluation of the paranasal sinuses in children. Am J Roentgenol Radium Ther Nucl Med 1973; 118:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6343 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17561=[""].join("\n");
var outline_f17_9_17561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ineffective cough",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Specific cough",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Key symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nonspecific cough",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Age and circumstances at onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nature of the cough",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Timing and triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Past medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Social history and environmental exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      General examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chest examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CHEST RADIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PULMONARY FUNCTION TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      BRONCHOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Esophageal pH monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Sinus imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Tuberculin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Allergy testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6343\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6343|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/57/24471\" title=\"algorithm 1\">",
"      Chronic cough child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6343|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/15/16630\" title=\"diagnostic image 1A\">",
"      Bronchiectasis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/46/16100\" title=\"diagnostic image 1B\">",
"      Bronchiectasis Lateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/11/13489\" title=\"diagnostic image 2\">",
"      Normal thymus in an infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6343|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/15/34046\" title=\"figure 1\">",
"      Mechanisms cough reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6343|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/23/17789\" title=\"table 1\">",
"      Causes persistent cough in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/57/18333\" title=\"table 2\">",
"      Specific cough child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/20/15692\" title=\"table 3\">",
"      Infectious cough worldwide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=related_link\">",
"      Approach to the infant and child with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=related_link\">",
"      Causes of chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28025?source=related_link\">",
"      Clinical manifestations and diagnosis of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=related_link\">",
"      Congenital anomalies of the larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37896?source=related_link\">",
"      Hemoptysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=related_link\">",
"      Primary ciliary dyskinesia (immotile-cilia syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=related_link\">",
"      Wheezing illnesses other than asthma in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_9_17562="Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation";
var content_f17_9_17562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17562/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17562/contributors\">",
"     Karen Hardinger, PharmD, BCPS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17562/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17562/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/9/17562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/9/17562/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/9/17562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two commercially available mammalian target of rapamycin inhibitors FDA approved in the United States:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    . Sirolimus (Rapamune&reg;, rapamycin) is a macrocyclic triene antibiotic that is produced by fermentation of Streptomyces hygroscopicus. Sirolimus was discovered from a soil sample collected in Rapa Nui, which is also known as Easter Island [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/1\">",
"     1",
"    </a>",
"    ]. Although it was originally developed as an antifungal agent, it was later found to have immunosuppressive and antiproliferative properties that may be useful to treat or prevent proliferative diseases such as tuberous sclerosis, psoriasis, and malignancy. In April 2010 everolimus (Zortress&reg;), an analog of sirolimus and macrolide immunosuppressive agent, was approved by the FDA.",
"   </p>",
"   <p>",
"    The pharmacology of the mTOR inhibitors and their use and efficacy in renal transplant recipients will be reviewed here. A discussion of immunosuppressive therapy in renal transplant recipients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following entry into the cytoplasm,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    bind to the FK binding protein and presumably modulate the activity of the mammalian target of rapamycin (mTOR) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/2\">",
"     2",
"    </a>",
"    ]. The mTOR inhibits interleukin-2 mediated signal transduction, resulting in cell cycle arrest in the G1-S phase [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Sirolimus and everolimus block the response of T- and B-cell activation by cytokines, which prevents cell-cycle progression and proliferation; in contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    inhibit the production of cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    also appears to inhibit proliferation of smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/5\">",
"     5",
"    </a>",
"    ], and, since there is activation of the sirolimus target in tuberous sclerosis lesions, may dampen the growth of angiomyolipomas with tuberous sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/6\">",
"     6",
"    </a>",
"    ]. Sirolimus may also have anti-malignancy potential. In March 2009,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    (Afinitor&reg;) received approval for treatment of advanced renal cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Absorption",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Peak concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time to peak concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    is one to two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bioavailability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean bioavailability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    oral solution is 14 percent. When compared to the oral solution, sirolimus tablets have a 27 percent higher bioavailability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ]. The rate and extent of oral absorption of sirolimus may be reduced in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Effects of food",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    are altered by concurrent food intake. In 22 healthy volunteers, for example, the administration of sirolimus and a high fat breakfast resulted in a 34 percent decrease in the maximum concentration (Cmax), a 3.5-fold increase in the time to Cmax, and a 35 percent increase in the area under the concentration-time curve of sirolimus when compared to the fasting state [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. To minimize sirolimus variability caused by food [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ], we prefer to have patients take sirolimus at 8 AM, usually one to two hours after food ingestion. Everolimus should be taken consistently with or without food [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean volume of distribution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is 12",
"    <span class=\"nowrap\">",
"     L/kg,",
"    </span>",
"    with 97 percent of the agent being bound to albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ]. The highest concentration of sirolimus is found in red blood cells (95 percent). This is followed by plasma (3 percent), lymphocytes (1 percent), and granulocytes (1 percent); usual",
"    <span class=\"nowrap\">",
"     blood/plasma",
"    </span>",
"    ratios are about 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/4,7,9-11\">",
"     4,7,9-11",
"    </a>",
"    ]. In animal studies, high concentrations have been found in heart, intestines, kidneys, liver, spleen, muscle, lungs, and testes.",
"    <span class=\"nowrap\">",
"     Tissue/blood",
"    </span>",
"    ratios have usually been greater than 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , plasma protein binding is approximately 74 percent in healthy subjects and in patients with moderate hepatic impairment. The apparent distribution volume from a single-dose pharmacokinetic study in maintenance kidney transplant patients is 342 to 107 L (range 128 to 589 L) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    are extensively metabolized in the liver, and are substrates for cytochrome P450 3A4 and P-glycoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ]. The extent of metabolism of sirolimus in the intestinal wall is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Sirolimus is counter-transported in the gut lumen by P-glycoprotein. These processes account for low bioavailability and high pharmacokinetic variability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/4,10,12\">",
"     4,10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metabolites contribute to less than 10 percent of immunosuppressive activity of the parent compound,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . Known metabolites include hydroxysirolimus, desmethylsirolimus, and hydroxymethylsirolimus. An investigational immunosuppressant, RAD, (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    ) is the 40-O-(2 hydroxyethyl) derivative of sirolimus. Everolimus has six predominant metabolites, all with minimal immunosuppressive activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is 127 to 240",
"    <span class=\"nowrap\">",
"     mL/hr",
"    </span>",
"    per kg [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/4,7,9,13\">",
"     4,7,9,13",
"    </a>",
"    ]. Large intersubject variability occurs in the oral clearance of sirolimus, which has been reported to be 45 percent higher in black patients when compared to non-black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    are mainly excreted in the feces with a small percent in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The elimination half-life of sirolimus is 57 to 63 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/4,7,10,13\">",
"     4,7,10,13",
"    </a>",
"    ], which enables once daily dosing. Everolimus has a shorter half-life of approximately 30 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DOSAGE AND AVAILABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is available in a 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    oral solution (60 mL) and a 0.5, 1, and 2 mg triangular shaped tablet. Although the oral solution and tablet are not bioequivalent, clinical equivalence has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is available as a 0.25, 0.5, and 0.75 mg round, flat tablet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adult kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of initial immunosuppressive regimens after kidney transplant have included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as a component of a regimen that includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In these trials, a onetime loading dose of 6 mg or 15 mg (3 times the maintenance dose) followed by a maintenance dose of either 2 or 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was utilized.",
"   </p>",
"   <p>",
"    An initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    dose of 0.75 mg orally twice daily is recommended for adult kidney transplant patients in combination with reduced dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical practice, dosage adjustments for both mTOR inhibitors are made based upon several factors including concomitant administration of P450 enzyme inducers or inhibitors, hepatic insufficiency, toxicity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    are available in the geriatric and pediatric populations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Organ impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosage adjustment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is not required in the presence of renal impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, dosage reductions of approximately one-third the normal maintenance dose should be used for patients with hepatic impairment.",
"   </p>",
"   <p>",
"    In patients with moderate hepatic impairment (Child-Pugh class B), the daily dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    needs to be reduced by one-half the recommended initial daily dose. There is no information on the effects of severe hepatic impairment (Child-Pugh class C) on everolimus pharmacokinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Close monitoring of mTOR inhibitors with whole-blood concentrations is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     THERAPEUTIC DRUG MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Steady-state concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steady-state concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    occur five to seven days after initiation of therapy or a change in dose. During clinical trials, mean sirolimus whole-blood trough concentrations (determined by immunoassay) were 9",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (range, 4.5 to 14",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and 17",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (range, 10 to 28",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    in the 2 and 5 mg treatment groups, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Routine therapeutic drug monitoring",
"    </span>",
"   </p>",
"   <p>",
"    An excellent correlation exists between trough whole-blood levels and the area under the time-concentration curve for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Routine therapeutic drug monitoring of sirolimus blood concentrations is recommended for all patients.",
"   </p>",
"   <p>",
"    In clinical practice,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    whole blood concentrations are being measured by both chromatographic and immunoassay methodologies. The recommended time for collection is one hour prior to the next oral dose. Whole-blood samples should be collected in tubes with EDTA and protected from light; samples collected in this fashion are stable for 24 hours at room temperature, up to one week at 2 to 8 degrees centigrade, and up to three months at -20 degrees centigrade.",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , trough whole-blood sirolimus concentrations of 5 to 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were associated with protection from acute rejection episodes and adverse effects. Sirolimus trough concentrations greater than 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    have been correlated with hypertriglyceridemia, thrombocytopenia and leukopenia. Sirolimus concentrations less than 5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were associated with the occurrence of acute rejection in renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is used with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , higher trough concentrations may be necessary. In a clinical trial of renal transplant recipients, sirolimus trough concentrations were maintained at 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for the first two months posttransplant then reduced to 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    thereafter. Acute rejection episodes were reported in 28 to 41 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring the phosphorylation status of p70S6 kinase in peripheral blood mononuclear cells has been proposed as an alternative strategy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine monitoring of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    trough concentrations is recommended in all patients and the concentrations should fall within the 3 to 8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    target range [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/8\">",
"     8",
"    </a>",
"    ]. Optimally, dose adjustments of everolimus should be based on trough concentrations obtained four or five days after a previous dosing change [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/20-24\">",
"     20-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is associated with a number of possible adverse effects, including leukopenia, thrombocytopenia, anemia, hypercholesterolemia, hypertriglyceridemia, diarrhea, and others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hematologic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia, thrombocytopenia, and leukopenia can be observed in those administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In clinical trials, anemia has been reported in 19 to 57 percent of patients, with variability based in part on time post-transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3,25,26\">",
"       3,25,26",
"      </a>",
"      ]. The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      may be associated with an enhanced incidence of anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombocytopenia has been observed in 8 to 30 percent of subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3,26\">",
"       3,26",
"      </a>",
"      ]. Reductions in platelet count are dose-related and usually occur 9 to 10 days after initiation of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Normalization of platelet counts is seen within two weeks of discontinuation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukopenia, which does not appear to be dose-related, is evident within two weeks of initiation of therapy and is reversible upon discontinuation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. In one study, among 64 patients administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      in a randomized trial (target trough concentration of 6 to 12",
"      <span class=\"nowrap\">",
"       ng/ml),",
"      </span>",
"      7 (11 percent) developed leukopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     HUS/Thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic uremic syndrome",
"    <span class=\"nowrap\">",
"     (HUS)/Thrombotic",
"    </span>",
"    microangiopathy has been reported with the combination",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"      cyclosporine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"      sirolimus",
"     </a>",
"    </span>",
"    immunosuppressive regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HUS was reported in one group of 10 patients administered",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"        sirolimus",
"       </a>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/30\">",
"       30",
"      </a>",
"      ]. These patients were noted to have higher cyclosporine and sirolimus levels than those without HUS and discontinuation of these agents resulted in reversal of HUS in most cases. Of note, the incidence of HUS at this center was lower on a regimen of cyclosporine and sirolimus when compared to historic controls on a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or cyclosporine based regimen without sirolimus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single-center cohort study, 13 of 368 patients developed biopsy proven thrombotic microangiopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/31\">",
"       31",
"      </a>",
"      ]. The incidence was highest with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"        sirolimus",
"       </a>",
"      </span>",
"      (20 percent, 6 patients) compared with other regimens, including cyclosporine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      plus mycophenolate, and tacrolimus plus sirolimus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased rate of hepatic artery thrombosis, graft loss, and death has also been reported in liver transplant recipients. In two multicenter, randomized trials in de novo liver transplant recipients, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    in combination with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    was associated with an increased rate of hepatic artery thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, in one phase II study, the use of sirolimus and tacrolimus was associated with an increased rate of death and graft loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Metabolic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia (23 to 57 percent) and hypercholesterolemia (38 to 46 percent) are dose-related effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    therapy that occur via the inhibition of lipoprotein lipase [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/26,33-35\">",
"     26,33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term exposure to rapamycin may also cause deterioration of glucose metabolism and promote new onset diabetes after transplantation. For a discussion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and post-transplant diabetes mellitus, (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Gastrointestinal system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common gastrointestinal adverse events include constipation (28 to 36 percent), diarrhea (25 to 42 percent), dyspepsia (17 to 25 percent), nausea (25 to 36 percent), and vomiting (19 to 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3,26\">",
"     3,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mouth sores, not related to herpes simplex virus, have been reported in some patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      oral solution. This is probably dose-related. In addition, oral ulcers may occur with the combination of sirolimus and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil and may be seen more frequently in steroid-avoidance protocols [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. In a study cited above, among 64 patients administered sirolimus in a randomized trial (target trough concentration of 6 to 12",
"      <span class=\"nowrap\">",
"       ng/ml),",
"      </span>",
"      24 (38 percent) developed aphthous ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Respiratory system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive interstitial pneumonitis has been observed in a number of transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3,26,38-41\">",
"     3,26,38-41",
"    </a>",
"    ] with an incidence of 22 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/26\">",
"     26",
"    </a>",
"    ]. Increased risk factors for pneumonitis include a late switch to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and impaired renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/41\">",
"     41",
"    </a>",
"    ]. Clinical symptoms consist of dyspnea, dry cough, fever, and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/40\">",
"     40",
"    </a>",
"    ]. In one report of 24 patients, radiographic and bronchoalveolar lavage principally revealed bronchiolitis olibertans-organizing pneumonia and lymphocytic alveolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Complete recovery was observed in all patients within six months of sirolimus withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Kidney function",
"    </span>",
"    &nbsp;&mdash;&nbsp;As shown in animals,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is minimally nephrotoxic when used alone, although there are no definitive data in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the combination of sirolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has caused synergistic nephrotoxicity in animals and humans [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/39\">",
"     39",
"    </a>",
"    ], which may be due to increased renal and whole blood levels of cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/43\">",
"     43",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the resultant increase in the fibrogenic cytokine TGF-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During phase III clinical trials that used combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , the mean serum creatinine concentration and glomerular filtration rates were increased and decreased, respectively. These effects were not observed with cyclosporine and placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    controls. In addition, the combination of sirolimus plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , compared with",
"    <span class=\"nowrap\">",
"     tacrolimus/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"      mycophenolate",
"     </a>",
"    </span>",
"    regimens, is consistently associated with decreased renal function in several prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal function should therefore be carefully monitored in patients treated with combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and a calcineurin inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also some evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    may be associated with delayed allograft function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In a study of 144 first deceased or living donor kidney allograft recipients, delayed graft function was significantly more common in patients treated with rapamycin than without this agent (25 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/52\">",
"     52",
"    </a>",
"    ]. However, given that these were retrospective non-randomized studies, these results may reflect bias that sirolimus may have been administered because of the perception of less nephrotoxicity with this agent.",
"   </p>",
"   <p>",
"    Issues related to renal function, calcineurin inhibitor withdrawal, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    are discussed below. (See",
"    <a class=\"local\" href=\"#H1802441899\">",
"     'Use in renal transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    has also been associated with proteinuria and a glomerulonephropathy (particularly focal segmental glomerulosclerosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/26,53-66\">",
"     26,53-66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study of 68 renal transplant recipients in whom",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      was substituted for a calcineurin-inhibitor, proteinuria was assessed prior to and at 3, 6, 12, and 24 months after the substitution [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/57\">",
"       57",
"      </a>",
"      ]. Compared with baseline levels (mean of 0.36",
"      <span class=\"nowrap\">",
"       grams/day),",
"      </span>",
"      proteinuria markedly increased at 3, 6, 12, and 24 months (1.35, 1.67, 1.27, and 1.14",
"      <span class=\"nowrap\">",
"       grams/day,",
"      </span>",
"      respectively). Proteinuria was reversible among the 19 patients in whom sirolimus was withdrawn (1.95 to 0.9",
"      <span class=\"nowrap\">",
"       grams/day).",
"      </span>",
"     </li>",
"     <li>",
"      In one study of patients converted to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , 64 percent developed proteinuria, with 30 percent of these developing FSGS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A collapsing form of focal segmental glomerulosclerosis has been associated with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , which had been used to treat a patient with Kaposi's sarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/55\">",
"       55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=see_link\">",
"       \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible mechanisms for proteinuria with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    involve reduced tubular protein reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/67\">",
"     67",
"    </a>",
"    ], podocyte dysregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/63\">",
"     63",
"    </a>",
"    ], and overexpression of vascular endothelial growth factor that enhances cell wall permeability leading to collapsing focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A unique form of cast nephropathy has been described in a few patients with delayed allograft function and extensive tubular damage who were being administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/52\">",
"     52",
"    </a>",
"    ]. Casts were histologically indistinguishable from those observed with myeloma nephropathy.",
"   </p>",
"   <p>",
"    Acute renal failure occurring in association with myoglobinuria and myoglobulin-appearing casts has also been reported in patients administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/68\">",
"     68",
"    </a>",
"    ]. Additional reports have noted an increased risk of delayed allograft function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1802441899\">",
"     'Use in renal transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttransplant lymphoproliferative disease (PTLD) is uncommon among those administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . There is also some evidence that sirolimus may actually have anti-malignancy effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .) However, in a retrospective review of Medicare claims data for transplant recipients who underwent transplant from January 2000 to September 2006, de novo use of sirolimus was associated with a 22 percent increased risk of PTLD (HR 1.22, 95% CI 1.03&ndash;1.45) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Teratogenicity/effects in pregnancy and fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is contraindicated in pregnancy and its use should also be discontinued at least 12 weeks prior to attempted conception [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=see_link\">",
"     \"Sirolimus: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, we recommend that women post-transplant who wish to conceive be switched prior to conception from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Upon delivery, it is our general practice to switch the mother back to her basal immunosuppression in view of the potential benefits of the newer agents to prevent late acute rejection and chronic allograft nephropathy.",
"   </p>",
"   <p>",
"    There is also some evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is associated with impaired spermatogenesis. In an observational study of 95 kidney transplant patients, the total sperm count was significantly lower among those who received sirolimus (29 x 10(6) versus 292 x 10(6)) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/71\">",
"     71",
"    </a>",
"    ]. In addition, patients receiving a sirolimus-based regimen had a significantly decreased fathered pregnancy rate compared with those administered a sirolimus-free regimen (5.9 versus 92.9",
"    <span class=\"nowrap\">",
"     pregnancies/1000",
"    </span>",
"    patient years). Thus, men who desire to father children should be informed of the risks and benefits associated with exposure to sirolimus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two case reports,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    has been associated with the development of leukocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Sirolimus is also associated with post-operative wound complications. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10133?source=see_link\">",
"     \"Issues relating to the renal allograft recipient undergoing non-transplant surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There appears to be an increased incidence of angioedema in patients administered angiotensin-converting enzyme (ACE) inhibitors plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. This was best shown in a retrospective study of 309 patients administered either sirolimus (144) or everolimus (165), with 137 also being treated with ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/75\">",
"     75",
"    </a>",
"    ]. Combined therapy was associated with a 6.6 percent incidence of angioedema, compared with a 1 to 2 percent incidence in those not being administered the combined regimen.",
"   </p>",
"   <p>",
"    A large number of cutaneous adverse events can be observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. In one study from France, skin disorders were reported in 79 of 80 renal transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/76\">",
"     76",
"    </a>",
"    ]; the most frequent were acne-like eruptions (46 percent), scalp folliculitis (26 percent), hidradenitis suppurativa (12 percent), edema (55 percent), angioedema (15 percent), aphthous ulceration (60 percent), and epistaxis (60 percent).",
"   </p>",
"   <p>",
"    Pericardial effusion has been noted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . Although most have been reported in cardiac transplant recipients, cases of pericardial effusion were observed in kidney transplant patients given sirolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To date",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    has not been compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    in a head-to-head trial, but in non-comparative trials, the side effects are similar. In trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    to everolimus in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , the most common adverse reactions observed in the everolimus group were peripheral edema, constipation, hypertension, nausea, anemia, urinary tract infection, and hyperlipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    are substrates for cytochrome P450 3A, the coadministration of sirolimus with cytochrome P450 3A inducers (such as some anticonvulsants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , St. John's Wort) and with cytochrome P450 3A inhibitors (such as azole antifungals, nondihydropyridine calcium channel blockers, some macrolide antibiotics, grapefruit) can result in significant interactions. Detail concerning mTOR inhibitor drug interactions, and suggestions for their management, are described in the table (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"     table 1",
"    </a>",
"    ). Additional information is available in the Lexi-Interact&trade; drug interactions program provided by UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    results in significantly higher",
"    <span class=\"nowrap\">",
"     peak/trough",
"    </span>",
"    levels and area under the concentration-time curve (AUC) when compared to their administration four hours apart [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/79\">",
"     79",
"    </a>",
"    ]. This was shown in a single dose drug interaction study in which sirolimus 10 mg and cyclosporine 300 mg (Neoral&reg;) oral soft gelatin capsules were administered either simultaneously or four hours apart [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/79\">",
"     79",
"    </a>",
"    ]. When given together, the sirolimus mean maximum concentration (Cmax) and area under the concentration-time curve (AUC) were increased by 116 percent and 230 percent, respectively, relative to administration of sirolimus alone. Whole-blood trough levels increased by about 30 percent with concomitant dosing, and the time to peak levels was also shorter (1.8 versus 2.5 hours). By comparison, when sirolimus was given four hours after cyclosporine, the Cmax and AUC were increased by 37 percent and 80 percent, respectively, compared to administration of sirolimus alone. The mean cyclosporine Cmax and AUC were not significantly affected by sirolimus when given concomitantly or four hours after cyclosporine.",
"   </p>",
"   <p>",
"    Because of these drug interactions and additive side effects (hypertriglyceridemia, possibly",
"    <span class=\"nowrap\">",
"     HUS/TTP)",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , we prefer",
"    <strong>",
"     not",
"    </strong>",
"    to use cyclosporine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . Nevertheless, when we do use the combination of cyclosporine and sirolimus, it is usually in the setting of administering sirolimus as either rescue therapy or to help reduce cyclosporine toxicity. In this setting, it is recommended that the time of administration of sirolimus be consistent with that of the administration of cyclosporine.",
"   </p>",
"   <p>",
"    In a single-dose study in healthy subjects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    administered at a dose of 175 mg increased",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    area under the curve by 168 percent (range 46 to 365 percent) and Cmax by 82 percent when administered with 2 mg everolimus compared with administration of everolimus alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    have different mechanisms of action, they share the same binding protein (FKBP-12) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/2\">",
"     2",
"    </a>",
"    ]. Initial in vitro experiments reported an antagonist effect between sirolimus and tacrolimus. However, because of the ubiquitous nature of FKBP-12, in vivo studies of pharmacologic doses of sirolimus did not reveal competitive inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    does not have the same pharmacokinetic interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as does",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . In a cross-over study, simultaneous and separate (by four hours) administration of sirolimus and tacrolimus were compared. No significant interactions were found in pharmacokinetic parameters including AUC and Cmax [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A unique form of cast nephropathy has been described in a few patients with delayed allograft function and extensive tubular damage who were being administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/52\">",
"     52",
"    </a>",
"    ]. Casts were histologically indistinguishable from those observed with myeloma nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study published in abstract form, the pharmacokinetic profiles of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    revealed a significantly higher mean AUC for mycophenolate in sirolimus-treated patients when compared to cyclosporine-treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/82\">",
"     82",
"    </a>",
"    ]. Similarly, mean mycophenolic acid trough concentrations were significantly higher in sirolimus treated patients. The authors concluded that, to avoid potential toxicity, mycophenolate dose reductions may be necessary when using the combination of mycophenolate mofetil and sirolimus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1802441899\">",
"    <span class=\"h1\">",
"     USE IN RENAL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    have been utilized in a number of settings in kidney transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Maintenance therapy",
"      </strong>",
"      &mdash; The efficacy of mTOR inhibitors for primary maintenance immunosuppressive therapy in kidney transplant recipients is well documented. However, early posttransplantation complications of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , particularly delayed allograft function, poor wound healing, adverse short-term outcomes, and an increased incidence of lymphoceles, have limited the de novo use of mTOR inhibitors at some centers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link&amp;anchor=H28#H28\">",
"       \"Maintenance immunosuppressive therapy in renal transplantation in adults\", section on 'Mammalian target of rapamycin inhibitors'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H19\">",
"       'Adverse effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10133?source=see_link\">",
"       \"Issues relating to the renal allograft recipient undergoing non-transplant surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Corticosteroid withdrawal",
"      </strong>",
"      &mdash; In an attempt to minimize corticosteroid induced morbidity,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      has been administered to renal transplant recipients in whom corticosteroids were eventually withdrawn. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=see_link\">",
"       \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic renal allograft nephropathy",
"      </strong>",
"      &mdash; A discussion of the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      in patients with chronic renal allograft nephropathy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"       \"Chronic renal allograft nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Refractory renal transplant rejection",
"      </strong>",
"      &mdash; The efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      for refractory renal allograft rejection has been evaluated in limited preliminary studies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/83\">",
"       83",
"      </a>",
"      ]. Further study is required to better understand the role of sirolimus in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4938?source=see_link\">",
"       \"Acute renal allograft rejection: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Experimental uses",
"      </strong>",
"      &mdash; The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      as monotherapy for maintenance immunosuppression was evaluated in a small open-label trial of 12 renal allograft recipients who received rabbit anti-thymocyte globulin for aggressive T cell depletion therapy (at twice the typical dose) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , with the subsequent use of sirolimus as single agent maintenance therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/9/17562/abstract/84\">",
"       84",
"      </a>",
"      ]. At 12 months, patient and allograft survival was 100 percent, with the mean creatinine concentration being 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (107",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Ten of twelve patients were maintained with sirolimus monotherapy. The regimen was tolerated well, and three patients had histologic evidence of acute cellular rejection. Further study is required to better understand the benefits and adverse effects of this regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     PATIENT INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    oral solution should be taken in the following manner:",
"   </p>",
"   <p>",
"    &nbsp;1. &nbsp;Empty the medication from the amber syringe into a glass or plastic container.",
"   </p>",
"   <p>",
"    &nbsp;2. &nbsp;Then, it should be vigorously stirred with two ounces of water or orange juice.",
"   </p>",
"   <p>",
"    &nbsp;3. &nbsp;After immediately drinking the mixture, the container should again be filled with an equal amount of fluid and consumed immediately.",
"   </p>",
"   <p>",
"    &nbsp;4. &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    should not be mixed with grapefruit juice",
"   </p>",
"   <p>",
"    &nbsp;5. &nbsp;The oral solution should be protected from light and stored under refrigeration at all times to prevent degradation.",
"   </p>",
"   <p>",
"    Additional information to convey to patients includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When monitoring trough levels, the patient should be instructed not to take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      before laboratory testing.",
"     </li>",
"     <li>",
"      Patients should be monitored for signs of thrombocytopenia (easy bruising and bleeding), leukopenia (fever and signs of infection), and anemia (fatigue and pallor).",
"     </li>",
"     <li>",
"      Patients should consume a low fat diet and exercise on a regular basis to prevent dyslipidemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1802439392\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two commercially available mammalian target of rapamycin (MTOR) inhibitors that are FDA approved in the United States including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      . Both have immunosuppressive and antiproliferative properties. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      block the response of T- and B-cell activation by cytokines, which prevents cell-cycle progression and proliferation; in contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      inhibit the production of cytokines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      are extensively metabolized in the liver, and are substrates for cytochrome P450 3A4 and P-glycoprotein. Dosage adjustment of sirolimus is not required in the presence of renal impairment but is for patients with hepatic impairment. Routine therapeutic drug monitoring of sirolimus blood concentrations is recommended for all patients. The recommended time for collection is one hour prior to the next oral dose. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Organ impairment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Therapeutic drug monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      is associated with a number of possible adverse effects, including leukopenia, thrombocytopenia, anemia, hypercholesterolemia, hypertriglyceridemia, diarrhea, new onset diabetes, and others. Hemolytic uremic syndrome",
"      <span class=\"nowrap\">",
"       (HUS)/Thrombotic",
"      </span>",
"      microangiopathy has been reported with the combination",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       /sirolimus",
"      </span>",
"      immunosuppressive regimen. Sirolimus has also been associated with a glomerulopathy. Renal function should be carefully followed. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      is contraindicated in pregnancy. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Teratogenicity/effects in pregnancy and fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      are substrates for cytochrome P450 3A, the coadministration of sirolimus with cytochrome P450 3A inducers (such as some anticonvulsants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , St. John's Wort) and with cytochrome P450 3A inhibitors (such as azole antifungals, nondihydropyridine calcium channel blockers, some macrolide antibiotics, grapefruit) can result in significant interactions. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Concurrent administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      results in significantly higher",
"      <span class=\"nowrap\">",
"       peak/trough",
"      </span>",
"      levels and area under the concentration-time curve (AUC) when compared to their administration four hours apart. Because of these drug interactions and additive side effects (hypertriglyceridemia, possibly",
"      <span class=\"nowrap\">",
"       HUS/TTP)",
"      </span>",
"      with cyclosporine, we prefer",
"      <strong>",
"       not",
"      </strong>",
"      to use cyclosporine with sirolimus. Nevertheless, when we do use the combination of cyclosporine and sirolimus, (usually in the setting of administering sirolimus as either rescue therapy or to help reduce cyclosporine toxicity), we suggest that the time of administration of sirolimus be consistent with that of the administration of cyclosporine. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      have been utilized in a number of settings in kidney transplantation including maintenance therapy, particularly in settings in which corticosteroids are withdrawn, chronic renal allograft nephropathy and in refractory renal transplant rejection. (See",
"      <a class=\"local\" href=\"#H1802441899\">",
"       'Use in renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/1\">",
"      Sehgal SN, Baker H, V&eacute;zina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/2\">",
"      Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 2004; 24:1159.",
"     </a>",
"    </li>",
"    <li>",
"     Product Information: Rapamune&reg; (sirolimus) Oral Solution and Tablets, Wyeth Laboratories, Division of Wyeth-Ayerst Pharmaceuticals Inc., Philadelphia, PA, 1/2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/4\">",
"      Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/5\">",
"      Cao W, Mohacsi P, Shorthouse R, et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/6\">",
"      El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003; 361:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/7\">",
"      Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37:405.",
"     </a>",
"    </li>",
"    <li>",
"     Product Information: Zortress&reg; (everolimus) Tablets, Novartis Pharmaceutical Corporation, East Hanover, New Jersey,  4/2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/9\">",
"      Kahan BD, Napoli KL. Role of therapeutic drug monitoring of rapamycin. Transplant Proc 1998; 30:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/10\">",
"      Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther 1997; 61:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/11\">",
"      Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation 1993; 56:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/12\">",
"      Briffa N, Morris RE. New immunosuppressive regimens in lung transplantation. Eur Respir J 1997; 10:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/13\">",
"      Yatscoff RW, Wang P, Chan K, et al. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995; 17:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/14\">",
"      Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/15\">",
"      MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/16\">",
"      Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/17\">",
"      Groth CG, B&auml;ckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/18\">",
"      Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/19\">",
"      Hartmann B, Schmid G, Graeb C, et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int 2005; 68:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/20\">",
"      Chan L, Hartmann E, Cibrik D, et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 2010; 90:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/21\">",
"      Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010; 23:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/22\">",
"      Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/23\">",
"      Vitko, S, Margreiter, R, Weimar, W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Erratum in Am J Transplant 2006; 6:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/24\">",
"      V&iacute;tko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/25\">",
"      Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/26\">",
"      Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/27\">",
"      Griny&oacute; JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006; 6:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/28\">",
"      Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/29\">",
"      Groth CG, Brattstr&ouml;m C, Claesson K, B&auml;ckman L. New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation. Transplant Proc 1998; 30:4064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/30\">",
"      Langer RM, Van Buren CT, Katz SM, Kahan BD. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine a sirolimus combination. Transplant Proc 2001; 33:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/31\">",
"      Fortin MC, Raymond MA, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 2004; 4:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/32\">",
"      Crew RJ, Radhakrishnan J, Cohen DJ, et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant 2005; 20:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/33\">",
"      Kraemer FB, Takeda D, Natu V, Sztalryd C. Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways. Metabolism 1998; 47:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/34\">",
"      Brattstr&ouml;m C, Wilczek HE, Tyd&eacute;n G, et al. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 1998; 30:3950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/35\">",
"      Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/36\">",
"      van Gelder T, ter Meulen CG, Hen&eacute; R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/37\">",
"      Smith MP, Newstead CG, Ahmad N, et al. Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation. Transplantation 2008; 85:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/38\">",
"      Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/39\">",
"      Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/40\">",
"      Champion L, Stern M, Isra&euml;l-Biet D, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/41\">",
"      Weiner SM, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature. Nephrol Dial Transplant 2007; 22:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/42\">",
"      Sabbatini M, Sansone G, Uccello F, et al. Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. Transplantation 2000; 69:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/43\">",
"      Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/44\">",
"      Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/45\">",
"      Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/46\">",
"      Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006; 6:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/47\">",
"      Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/48\">",
"      Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/49\">",
"      Kaplan B, Kirk AD. Tacrolimus and sirolimus: when bad things happen to good drugs. Am J Transplant 2006; 6:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/50\">",
"      McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/51\">",
"      Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/52\">",
"      Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/53\">",
"      Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004; 17:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/54\">",
"      Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/55\">",
"      Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/56\">",
"      Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/57\">",
"      Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/58\">",
"      Sennesael JJ, Bosmans JL, Bogers JP, et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005; 80:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/59\">",
"      Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35:52S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/60\">",
"      Horita Y, Miyazaki M, Koji T, et al. Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis. Nephrol Dial Transplant 1998; 13:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/61\">",
"      Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/62\">",
"      Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006; 82:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/63\">",
"      Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/64\">",
"      Diekmann F, Guti&eacute;rrez-Dalmau A, L&oacute;pez S, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant 2007; 22:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/65\">",
"      Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/66\">",
"      Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/67\">",
"      Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006; 6:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/68\">",
"      Pelletier R, Nadasdy T, Nadasdy G, et al. Acute renal failure following kidney transplantation associated with myoglobinuria in patients treated with rapamycin. Transplantation 2006; 82:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/69\">",
"      Nee R, Hurst FP, Dharnidharka VR, et al. Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation 2011; 92:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/70\">",
"      European Best Practices Guidelines (Part 2). Nephrol Dial Transplant 2002; 17(Suppl 4):50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/71\">",
"      Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008; 8:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/72\">",
"      Hardinger KL, Cornelius LA, Trulock EP 3rd, Brennan DC. Sirolimus-induced leukocytoclastic vasculitis. Transplantation 2002; 74:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/73\">",
"      Pasqualotto AC, Bianco PD, Sukiennik TC, et al. Sirolimus-induced leukocytoclastic vasculitis: the second case reported. Am J Transplant 2004; 4:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/74\">",
"      Stallone G, Infante B, Di Paolo S, et al. Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant 2004; 19:2906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/75\">",
"      Duerr M, Glander P, Diekmann F, et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/76\">",
"      Mah&eacute; E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/77\">",
"      Desai N, Heenan S, Mortimer PS. Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism. Br J Dermatol 2009; 160:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/78\">",
"      Steele GH, Adamkovic AB, Demopoulos LA, et al. Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety database. Transplantation 2008; 85:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/79\">",
"      Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998; 63:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/80\">",
"      Chen H, Qi S, Xu D, et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. Transplant Proc 1998; 30:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/81\">",
"      McAlister VC, Mahalati K, Peltekian KM, et al. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/82\">",
"      Holt, DW, Ostraat, O, Grinyo, JM, et al. MMF may be given at lower doses when used in association with sirolimus in renal transplant recipients (abstract). Am J Transplant 2001; 1(Suppl 1):247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/83\">",
"      Hong JC, Kahan BD. Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantation 2001; 71:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/9/17562/abstract/84\">",
"      Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360:1662.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7329 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-9ACE31C43F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17562=[""].join("\n");
var outline_f17_9_17562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1802439392\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Peak concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bioavailability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Effects of food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DOSAGE AND AVAILABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adult kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Organ impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      THERAPEUTIC DRUG MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Steady-state concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Routine therapeutic drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hematologic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - HUS/Thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Metabolic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Gastrointestinal system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Respiratory system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Kidney function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Teratogenicity/effects in pregnancy and fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1802441899\">",
"      USE IN RENAL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      PATIENT INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1802439392\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7329|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/44/15042\" title=\"table 1\">",
"      Drug interactions with immunosuppressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10133?source=related_link\">",
"      Issues relating to the renal allograft recipient undergoing non-transplant surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=related_link\">",
"      Sirolimus: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=related_link\">",
"      Withdrawal or avoidance of glucocorticoids after renal transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_9_17563="Risk factors chorioamnionitis";
var content_f17_9_17563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for chorioamnionitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Advanced cervical dilatation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature labor resistant to tocolytic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature rupture of membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged rupture of membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple vaginal examinations during labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of an internal fetal monitoring electrode",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower gestational age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower birth weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal vaginal flora",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal immunodeficiency states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal bleeding",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17563=[""].join("\n");
var outline_f17_9_17563=null;
var title_f17_9_17564="TNM stage group urethra";
var content_f17_9_17564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cancer of the urethra: TNM stage groups",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Primary tumor (T)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Regional lymph nodes (N)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0a",
"      </td>",
"      <td>",
"       Ta",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       0is",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis pu",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis pd",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       III",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       IV",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17564=[""].join("\n");
var outline_f17_9_17564=null;
var title_f17_9_17565="Variation of MoM values by GA";
var content_f17_9_17565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    The impact of a two week discrepancy in dates on calculation of the MoM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 175px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient's gestational age at the time of blood draw was calculated to be 18 weeks based on her last menstrual period (LMP) and 16 weeks based on an early ultrasound examination. The AFP, uE3, and hCG mass values calculated to a low AFP, low uE3, and elevated hCG MoM for a pregnancy at 18 gestational weeks (green circles), leading to calculation of high risk of Down syndrome. However, the same mass values for a pregnancy at 16 gestational weeks (yellow circles) were on the unaffected median (1 MoM) for each analyte, leading to calculation of low risk of Down syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17565=[""].join("\n");
var outline_f17_9_17565=null;
var title_f17_9_17566="Spectrum of CHD";
var content_f17_9_17566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spectrum of coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_9_17566=[""].join("\n");
var outline_f17_9_17566=null;
var title_f17_9_17567="Contents: General surgical principles";
var content_f17_9_17567=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General surgical principles",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General surgical principles",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abdominal wall",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/39/21113\">",
"           Abdominal surgical incisions: Prevention and treatment of complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/18/17703\">",
"           Anatomy of the abdominal wall",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/23/22904\">",
"           Noninfectious complications of continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6136\">",
"           Placement and maintenance of the peritoneal dialysis catheter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/24/10633\">",
"           Principles of abdominal wall closure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30265\">",
"           Principles of abdominal wall incisions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/60/3018\">",
"           Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Minor procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33124\">",
"           Closure of minor skin wounds with staples",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/7/18553\">",
"           Closure of skin wounds with sutures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/51/32567\">",
"           Minor wound preparation and irrigation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/12/1226\">",
"           Placement and management of thoracostomy tubes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41478\">",
"           Superficial wound repair with tissue adhesives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Postoperative care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27546\">",
"           Management of postoperative pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/45/40666\">",
"           Perioperative medication management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/46/19178\">",
"           Postoperative fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2586\">",
"           Postoperative ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/20/34120\">",
"           Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1049\">",
"           Prevention of pressure ulcers",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Postoperative complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20761\">",
"           Abdominal compartment syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/3/3129\">",
"           Nerve injury associated with pelvic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2586\">",
"           Postoperative ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/20/34120\">",
"           Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1049\">",
"           Prevention of pressure ulcers",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgery basics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/23/19831\">",
"           A patient-centered view of the clinician-patient relationship",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/30/26087\">",
"           A short primer on cost-effectiveness analysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/39/21113\">",
"           Abdominal surgical incisions: Prevention and treatment of complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/18/17703\">",
"           Anatomy of the abdominal wall",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/18/44328\">",
"           Carbon dioxide monitoring (capnography)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5512\">",
"           Consent in adolescent health care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/61/24537\">",
"           Cross-cultural care and communication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/60/26565\">",
"           Ethics in the intensive care unit: Informed consent",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24934\">",
"           Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32887\">",
"           Ethics in the intensive care unit: Withholding and withdrawing life-support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/2/12330\">",
"           Hospital discharge",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15322\">",
"           Hospital management of older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43094\">",
"           Informed consent",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/8/14473\">",
"           Legal aspects of end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/12/17609\">",
"           Literacy and patient care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7930\">",
"           Management of healthcare personnel exposed to HIV",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/55/23416\">",
"           Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/49/37657\">",
"           Measuring quality in hospitals in the United States: Core process measures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33369\">",
"           Operating room safety",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31290\">",
"           Overview of control measures to prevent surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37737\">",
"           Overview of electrosurgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/55/39800\">",
"           Overview of preoperative evaluation and preparation for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/22/17769\">",
"           Overview of topical hemostatic agents used in the operating room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18931\">",
"           Patient information: Blood or body fluid exposure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/45/40666\">",
"           Perioperative medication management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/43/32439\">",
"           Preoperative assessment of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26359\">",
"           Preventing postoperative peritoneal adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/51/30521\">",
"           Prevention of adverse drug events in hospitals",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/53/31578\">",
"           Prevention of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41802\">",
"           Prevention of venous thromboembolic disease in surgical patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/24/10633\">",
"           Principles of abdominal wall closure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30265\">",
"           Principles of abdominal wall incisions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/32/9736\">",
"           Pulse oximetry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/34/11815\">",
"           Rapid response systems",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1930\">",
"           Reducing adverse obstetrical outcomes through safety sciences",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26105\">",
"           Retained surgical sponge (gossypiboma) and other retained surgical foreign bodies: Prevention and management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgical critical care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20761\">",
"           Abdominal compartment syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/61/40920\">",
"           Pain control in the critically ill adult patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgical drains",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/16/9480\">",
"           Nasogastric and nasoenteric tubes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/12/1226\">",
"           Placement and management of thoracostomy tubes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgical materials and devices",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/25/32151\">",
"           Basic principles of medical lasers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/12/1226\">",
"           Placement and management of thoracostomy tubes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/33/11799\">",
"           Reconstructive materials used in surgery: Classification and host response",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26105\">",
"           Retained surgical sponge (gossypiboma) and other retained surgical foreign bodies: Prevention and management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgical nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6664\">",
"           Perioperative nutritional support",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgical symptoms and signs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31927\">",
"           Approach to the adult with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/47/16120\">",
"           Approach to the adult with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/4/27720\">",
"           Approach to the patient with dyspepsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/14/17641\">",
"           Approach to the patient with night sweats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/36/34375\">",
"           Clinical manifestations and diagnosis of edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/30/16874\">",
"           Differential diagnosis of abdominal pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/17/12569\">",
"           Evaluation of dysphagia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41770\">",
"           Evaluation of the adult with abdominal pain in the emergency department",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Wound management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/63/27642\">",
"           Basic principles of wound management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/40/19078\">",
"           Clinical assessment of wounds",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26264\">",
"           Negative pressure wound therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/12/37064\">",
"           Treatment of pressure ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/3/5177\">",
"           Wound healing and risk factors for non-healing",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E00DB57EDE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f17_9_17567=[""].join("\n");
var outline_f17_9_17567=null;
